Anti-FcRn antibodies or antigen-binding fragments thereof with improved stability
By substituting specific amino acids into the variable regions of the light and heavy chains of anti-FcRn antibodies, the problem of insufficient antibody stability was solved, resulting in improved high affinity and bioactivity. This significantly reduced the level of pathogenic autoantibodies in the blood and effectively treated autoimmune diseases.
Patent Information
- Application Number
- CN202380032609.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-04-28
- Filing Date
- 2023-05-26
- Publication Date
- 2024-11-22
AI Technical Summary
Existing anti-FcRn antibodies suffer from insufficient stability and high aggregation rate when treating autoimmune diseases. They also have poor affinity and biological activity, and cannot effectively reduce the level of pathogenic autoantibodies in the blood.
By substituting specific amino acids into the light and heavy chain variable regions of the anti-FcRn antibody, such as replacing N3 with Ser or Gln, C2 with Ser or Tyr, and Q16 with Glu, the stability of the antibody can be improved, while maintaining high affinity and biological activity for FcRn.
It improves antibody stability, reduces aggregate formation rate, maintains high affinity and biological activity, significantly reduces the amount of pathogenic autoantibodies in the blood, and effectively treats autoimmune diseases.
Smart Images

Figure CN119013043A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS:
[0002] This application claims the benefit of Korean Patent Application No. 10-2022-0066176 filed on May 30, 2022, U.S. Provisional Patent Application No. 63 / 352,948 filed on June 16, 2022, U.S. Provisional Patent Application No. 63 / 370,772 filed on August 8, 2022, U.S. Provisional Patent Application No. 63 / 377,283 filed on September 27, 2022, and U.S. Provisional Patent Application No. 63 / 499,116 filed on April 28, 2023, the entireties of which are incorporated herein by reference.
[0003] References to sequence listings
[0004] The contents of the text named MUNO-008_001WO_SeqList.xml, created on May 25, 2023, and with a size of 61,442 words, are incorporated herein by reference. Technical Field
[0005] The present invention relates to an anti-FcRn antibody or an antigen-binding fragment thereof with improved stability and uses thereof. Background Art
[0006] The causes of autoimmune diseases have long been studied from the genetic, environmental and immunological perspectives, but the exact cause of the disease remains unclear. Recently, many studies have revealed that many autoimmune diseases are caused by IgG type autoantibodies. In fact, in studies for the diagnosis and treatment of autoimmune diseases, the relationship between the presence, absence or reduction of disease-specific autoantibodies and their therapeutic effects has been extensively studied.
[0007] The first-line drug for these autoimmune disease therapeutic agents is systemic high-dose steroid injection, and when symptoms are severe or difficult to control with steroids, high-dose IVIG (intravenous immunoglobulin) administration or plasmapheresis (plasmapheresis) is applied. When repeated use, high-dose steroids may weaken the effect or have serious side effects. The treatment cost of IVIG and plasmapheresis is high and there are various side effects and infection risks, so there is an urgent need to develop the therapeutic agent of this therapeutic field.
[0008] On the other hand, a therapeutic agent for autoimmune diseases using an FcRn antibody is being studied recently (Korean Patent Case No. 10-1815265). It is a drug with a new mechanism in which the antibody blocks FcRn (neonatal Fc receptor) involved in IgG recycling and increases the catabolism of IgG in the body, thereby reducing the level of the autoantibody to treat the disease. The anti-FcRn antibody is expected to be a product that can solve the problems of existing therapeutic agents.
[0009] However, in order to apply the antibody to severe autoimmune diseases caused by the production of autoantibodies against self-antigens in the body (such as pemphigus or neuromyelitis), it is necessary to develop antibodies that have stability while maintaining the affinity and biological activity of existing antibodies.
[0010] Background Technology Documents
[0011] Patent Documents
[0012] (Patent Document 1) KR10-1815265B Summary of the invention
[0013] Technical issues
[0014] Therefore, the present inventors produced a variant of the anti-FcRn antibody having improved stability by significantly reducing the generation rate of aggregates while maintaining the affinity and biological activity of the previously developed anti-FcRn antibody HL161AN.
[0015] Overview
[0016] In one aspect of the present invention, an anti-FcRn antibody or an antigen-binding fragment thereof is provided, comprising: a light chain variable region comprising a LCDR1 having an amino acid sequence as shown in SEQ ID NO: 1, a LCDR2 having an amino acid sequence as shown in SEQ ID NO: 2, and a LCDR3 having an amino acid sequence as shown in SEQ ID NO: 3; and a heavy chain variable region comprising a HCDR1 having an amino acid sequence as shown in SEQ ID NO: 5, a HCDR2 having an amino acid sequence as shown in SEQ ID NO: 6, and a HCDR3 having an amino acid sequence as shown in SEQ ID NO: 7, wherein the N3 amino acid in the amino acid sequence as shown in SEQ ID NO: 1 is substituted with another amino acid, or the C2 amino acid in the amino acid sequence as shown in SEQ ID NO: 5 is substituted with another amino acid. In some embodiments, the N3 amino acid in the amino acid sequence as shown in SEQ ID NO: 1 is substituted with Ser (S) or Gln (Q). In some embodiments, the C2 amino acid in the amino acid sequence as shown in SEQ ID NO: 5 is substituted with Ser (S) or Tyr (Y).
[0017] In another aspect of the present invention, an anti-FcRn antibody or antigen-binding fragment thereof is provided, which comprises a light chain variable region having an amino acid sequence as shown in SEQ ID NO:4 and a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:8; wherein the N25 amino acid in the amino acid sequence as shown in SEQ ID NO:4 is substituted with another amino acid; and the C32 or Q82 amino acid in the amino acid sequence as shown in SEQ ID NO:8 is substituted with another amino acid. In some embodiments, the N25 amino acid in the amino acid sequence as shown in SEQ ID NO:4 is substituted with Ser (S) or Gln (Q). In some embodiments, the C32 amino acid in the amino acid sequence as shown in SEQ ID NO:8 is substituted with Ser (S) or Tyr (Y). In some embodiments, the Q82 amino acid in the amino acid sequence as shown in SEQ ID NO:8 is substituted with Glu (E).
[0018] In some embodiments, the anti-FcRn antibodies or antigen-binding fragments thereof provided herein comprise a heavy chain variable region comprising a framework consisting of a framework region 1 (FR1) as shown in SEQ ID NO: 15, an amino acid sequence as shown in SEQ ID NO: 16, an amino acid sequence as shown in SEQ ID NO: 17, and an amino acid sequence as shown in SEQ ID NO: 18. FR4. In some embodiments, the Q16 amino acid in the amino acid sequence as shown in SEQ ID NO: 17 is substituted with another amino acid. In some embodiments, the Q16 amino acid in the amino acid sequence as shown in SEQ ID NO: 17 is substituted with Glu (E).
[0019] In some embodiments, an anti-FcRn antibody or an antigen-binding fragment thereof is provided, comprising: a light chain variable region comprising a LCDR1 having an amino acid sequence as shown in SEQ ID NO:9, a LCDR2 having an amino acid sequence as shown in SEQ ID NO:2, and a LCDR3 having an amino acid sequence as shown in SEQ ID NO:3; and a heavy chain variable region comprising a HCDR1 having an amino acid sequence as shown in SEQ ID NO:11, a HCDR2 having an amino acid sequence as shown in SEQ ID NO:6, and a HCDR3 having an amino acid sequence as shown in SEQ ID NO:7.
[0020] In some embodiments, the anti-FcRn antibody comprises an Fc region, wherein the Fc region is an IgG1 Fc region or an IgG4 Fc region. In some embodiments, the Fc region is an IgG1 Fc region comprising Leu234Ala and Leu235Ala amino acid substitutions. In some embodiments, the Fc region is an IgG4 Fc region comprising an S228P mutation.
[0021] Another aspect of the present invention provides a polynucleotide encoding the above-mentioned anti-FcRn antibody or antigen-binding fragment thereof.
[0022] Another aspect of the present invention provides a recombinant expression vector comprising the above polynucleotide.
[0023] Another aspect of the present invention provides a host cell transformed by the above recombinant expression vector.
[0024] Another aspect of the present invention provides a method for producing an anti-FcRn antibody or an antigen-binding fragment thereof, comprising:
[0025] Cultivating the host cells to produce antibodies; and separating and purifying the produced antibodies to recover antibodies that specifically bind to FcRn.
[0026] Another aspect of the present invention provides a pharmaceutical composition for treating an autoimmune disease, comprising the above-mentioned anti-FcRn antibody or an antigen-binding fragment thereof. In some embodiments, the autoimmune disease is selected from the group consisting of autoimmune neutropenia, Guillain-Barré syndrome, epilepsy, autoimmune encephalitis, Isaacs syndrome, nevus syndrome, pemphigus vulgaris, pemphigus exfoliativa, bullous pemphigus, epidermolysis bullosa acquisita, pemphigus gestationis, mucous membrane pemphigoid, antiphospholipid syndrome, autoimmune anemia, autoimmune Graves' disease, thyroid eye disease (TED), Goodpasture syndrome, myasthenia gravis, multiple sclerosis, rheumatoid arthritis, lupus, idiopathic thrombocytopenic purpura (ITP), warm autoimmune hemolytic anemia (WAIHA), chronic inflammatory demyelinating polyneuropathy (CIDP), lupus nephritis, IgA nephropathy (Berger's Disease), dermatomyositis, necrotizing autoimmune myopathy, and membranous nephropathy.
[0027] Another aspect of the present invention provides a method for treating an autoimmune disease in a subject in need thereof, comprising administering the above-mentioned anti-FcRn antibody or its antigen-binding fragment, or the above-mentioned pharmaceutical composition to the subject. In some embodiments, wherein the subject is human. In some embodiments, the autoimmune disease is selected from the group consisting of autoimmune neutropenia, Guillain-Barré syndrome, epilepsy, autoimmune encephalitis, Isaacs syndrome, nevus syndrome, pemphigus vulgaris, pemphigus exfoliatus, bullous pemphigus, acquired bullous epidermolysis bullosa, pemphigus gestationis, mucous membrane pemphigoid, antiphospholipid syndrome, autoimmune anemia, autoimmune Graves' disease, Goodpasture syndrome, myasthenia gravis, multiple sclerosis, rheumatoid arthritis, lupus, idiopathic thrombocytopenic purpura (ITP), lupus nephritis and membranous nephropathy.
[0028] In some embodiments, the administration is parenteral. In some embodiments, the administration is subcutaneous or intravenous. In some embodiments, the administration is a dose of 300 mg to 2400 mg. In some embodiments, the administration is once a week, once every two weeks, once every three weeks, or once a month. In some embodiments, the administration is a dose of 300 mg to 900 mg subcutaneously once a week. In some embodiments, the administration is a dose of 300 mg to 1800 mg subcutaneously once every two weeks. In some embodiments, the administration does not cause the subject's blood albumin level to decrease by more than 5% or more than 10% compared to the blood albumin level before administration of the anti-FcRn antibody or its antigen-binding fragment.
[0029] In some embodiments, the administration does not cause the subject's blood total cholesterol or low-density lipoprotein (LDL) level to increase by greater than 5% or greater than 10% compared to the blood total cholesterol or low-density lipoprotein (LDL) level before administration of the anti-FcRn antibody or antigen-binding fragment thereof.
[0030] Effects of the Invention
[0031] Compared with the parent antibody HL161AN, the FcRn-specific antibody of the present invention has improved stability, such as reduced aggregate generation rate, and has excellent productivity and biological activity. The antibody of the present invention not only has high affinity for FcRn, but also has or is expected to have high specificity and no immunogenicity or low immunogenicity, and it binds to FcRn to significantly reduce the amount of pathogenic autoantibodies in the blood. Therefore, it can be used to treat autoimmune diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 Flowchart designed for in silico simulation of the HL161AN variant.
[0033] Figure 2 The graphic shows the predicted HL161AN light chain post-translational modification (PTM) sites.
[0034] Figure 3 The graphic shows the predicted HL161AN heavy chain post-translational modification (PTM) sites.
[0035] Figure 4 The graph shows 100% sequence coverage confirmed by treating the HL161AN internal standard sample obtained from the HL161AN producing cell line (#8G7) with two enzymes: trypsin+Lys C mixture and chymotrypsin, respectively.
[0036] Figure 5 The graph shows the results of computer simulation design of HL161AN variants (above) and the analysis results of the antibody binding site (paratope) of HL161AN for human FcRn (below). Specifically, it shows the results of designing variants by engineering three amino acid sites (L: Asn25, H: Cys32, H: Gln82) that can affect the stability of the HL161AN antibody. Here, the ellipse represents the substitution site of the selected PTM site. In addition, the antibody binding site of HL161AN is indicated by bold, and the CDR region according to the IgBlast Kabat system is indicated by underlining. * indicates the substitution site of the selected amino acid.
[0037] Figure 6 The graph shows the SDS-PAGE results of the HL161AN variant.
[0038] Figure 7 The graph shows the SPR results for the HL161AN variant.
[0039] Figure 8 The graph shows the results obtained by confirming the binding of the HL161AN variant to hFcRn using FACS.
[0040] Fig. 9 The graph shows the results obtained by confirming the effect of HL161AN variant in blocking hFcRn by using FACS.
[0041] Fig.10 The graph shows the degree of increase in aggregation (1 mg / mL) of the HL161AN variant in the stability test performed under accelerated conditions at 40°C.
[0042] Fig.11 The graph shows the extent of increase in fragments (1 mg / mL) of the HL161AN variant in a stability test performed under accelerated conditions at 40°C.
[0043] Fig.12 The graph shows the results obtained by confirming the binding of hFcRn to 8 high-concentration HL161AN variants, which were selected after the first in vitro screening, using FACS.
[0044] Fig.13 The graph shows the results obtained by confirming the hFcRn blocking effects of the eight high-concentration HL161AN variants, which were selected after the first in vitro screening, using FACS.
[0045] Fig.14 The graph shows the SDS-PAGE results of these eight high-concentration HL161AN variant samples.
[0046] Fig.15 The graph shows the SEC-HPLC results of these eight high-concentration HL161AN variant samples.
[0047] Fig.16 The graph shows the results obtained by comparing aggregate formation between HL161AN variant samples.
[0048] Fig.17The graph shows the results of the biotin-hIgG catabolism of the HL161AN variant (20 mg / kg) in Tg mice. It shows the results obtained by collecting blood 24, 48, 72, 96, 120 and 168 hours after tracer administration and measuring the biotin-hIgG concentration using ELISA.
[0049] Fig.18 The graph shows the reduction of IgG in monkeys after treatment with HL161ANS (IMVT-1402).
[0050] FIG. 19A to FIG. 19C The graphs show the albumin, LDL and cholesterol levels in monkeys after treatment with HL161ANS (IMVT-1402), respectively.
[0051] Fig. 20 Schematic diagram showing the design of the clinical study described in Example 13. Abbreviations: AUC = area under the concentration-time curve; Cmax = maximum observed concentration; IV = intravenous; MAD = multiple ascending dose; PK = pharmacokinetics; QW = once weekly; SAD = single ascending dose; SC = subcutaneous. DETAILED DESCRIPTION
[0052] In one aspect of the present invention, an anti-FcRn antibody or an antigen-binding fragment thereof with improved stability is provided, which comprises a light chain variable region comprising LCDR1 having an amino acid sequence as shown in SEQ ID NO:1, LCDR2 having an amino acid sequence as shown in SEQ ID NO:2, and LCDR3 having an amino acid sequence as shown in SEQ ID NO:3; and a heavy chain variable region comprising HCDR1 having an amino acid sequence as shown in SEQ ID NO:5, HCDR2 having an amino acid sequence as shown in SEQ ID NO:6, and HCDR3 having an amino acid sequence as shown in SEQ ID NO:7.
[0053] Thereafter, the N3 amino acid in the amino acid sequence as shown in SEQ ID NO:1 may be substituted with another amino acid, or the C2 amino acid in the amino acid sequence as shown in SEQ ID NO:5 may be substituted with another amino acid. "The N3 amino acid in the amino acid sequence as shown in SEQ ID NO:1" refers to the amino acid at position 3 (asparagine) in SEQ ID NO:1; and "the C2 amino acid in the amino acid sequence as shown in SEQ ID NO:5" refers to the amino acid at position 2 (cysteine) in SEQ ID NO:5.
[0054] As used herein, the term "FcRn" or "neonatal Fc receptor" is a MHC class I related protein that is expressed in vascular endothelial cells and binds to IgG and albumin. One feature is that when the pH value is weakly acidic, the binding between IgG and FcRn is strong, and there is no binding force at neutral pH values. Therefore, IgG that enters the cell by endocytosis or endocytosis strongly binds to the Fcγ receptors (FcγR) in the endosome under pH 6.0 conditions, thereby avoiding the degradation lysosomal pathway. After circulating back to the cell membrane, IgG rapidly dissociates from the FcRn in the blood at pH 7.4. It is well known that through this receptor-mediated recycling mechanism, FcRn effectively blocks the degradation of IgG in the lysosome, thereby extending the half-life of IgG. That is, FcRn binds to antibodies of the IgG isotype and recycles antibodies as a receptor, thereby playing an important role in maintaining the antibody level in serum.
[0055] On the other hand, it has been suggested that the serum half-life of IgG can be reduced by inhibiting the binding of IgG to FcRn, thereby treating autoimmune diseases caused by autoantibodies (Li et al., J. Clin. Invest., 115: 3440, 2005).
[0056] As used herein, the term "anti-FcRn antibody" is used interchangeably with "anti-FcRn antibody variant" and is an antibody specific for FcRn. Antibodies include intact antibody forms as well as antigen-binding fragments of antibodies.
[0057] In general, antibody molecules obtained from humans refer to any class of immunoglobulins (IgG, IgM, IgA, IgE and IgD), which differ from each other by the nature of the heavy chains present in the molecule. Certain classes also have subclasses, such as IgG1, IgG2, IgG3 or IgG4, etc. In addition, in humans, the light chain may be a kappa chain or a lambda chain. Therefore, in one embodiment, the antibodies disclosed herein are human IgG antibodies. In some embodiments, the antibodies are IgG1 antibodies. In some embodiments, the antibodies are IgG4 antibodies. In some embodiments, the anti-FcRn antibodies described herein are synthetic antibodies based on protein scaffolds that have the ability to bind to FcRn.
[0058] In some embodiments, the anti-FcRn antibody is a monoclonal antibody. The term "monoclonal antibody" (MAb or MAb) or "monoclonal antibody composition" as used herein refers to a population of antibody molecules containing only one antibody molecule, which consists of a unique light chain gene product and a unique heavy chain gene product.
[0059] As used herein, the term "antigen binding fragment" refers to one or more fragments of a complete antibody that retains the ability to specifically bind to a given antigen (i.e., FcRn). Antibody fragments in the present invention include single-chain antibodies, bispecific antibodies, trispecific antibodies, multispecific antibodies such as diabodies, triantibodies and tetrabodies, Fab fragments, F(ab')2 fragments, Fd, scFv, domain antibodies, bispecific antibodies, miniantibodies, scap (sterol-regulated binding protein cleavage activation protein), chelated recombinant antibodies, tribodies, diabodies, intracellular antibodies, nanobodies, SMIP (small modular immunopharmaceuticals), binding domain immunoglobulin fusion proteins, camel antibodies, VHH-containing antibodies, antibody constant region derivatives, but are not limited thereto.
[0060] The anti-FcRn antibodies or antigen-binding fragments provided herein may be humanized antibodies, human antibodies, chimeric antibodies, or murine antibodies.
[0061] It will be clear to those of ordinary skill in the art that any type of fragment of the antibody according to the present disclosure will exhibit the same properties as the antibody according to the present invention as long as the binding function to FcRn is maintained.
[0062] Exemplary CDR sequences of anti-FcRn antibodies disclosed herein are listed in Table 1. CDRs are defined according to the Kabat system.
[0063] [Table 1]
[0064]
[0065] In some embodiments, the anti-FcRn antibody or antigen-binding fragment thereof comprises: a light chain variable region comprising a LCDR1 having an amino acid sequence as shown in SEQ ID NO:1, a LCDR2 having an amino acid sequence as shown in SEQ ID NO:2, and a LCDR3 having an amino acid sequence as shown in SEQ ID NO:3; and a heavy chain variable region comprising a HCDR1 having an amino acid sequence as shown in SEQ ID NO:5, a HCDR2 having an amino acid sequence as shown in SEQ ID NO:6, and a HCDR3 having an amino acid sequence as shown in SEQ ID NO:7, wherein the N3 amino acid in the amino acid sequence as shown in SEQ ID NO:1 is substituted with another amino acid, and / or the C2 amino acid in the amino acid sequence as shown in SEQ ID NO:5 is substituted with another amino acid.
[0066] As used herein, the term "heavy chain (HC)" refers to a full-length heavy chain and fragments thereof comprising a variable region domain VH and three constant region domains CH1, CH2 and CH3, wherein the variable region structure VH comprises an amino acid sequence having sufficient variable region sequence to confer antigen specificity. In addition, as used herein, the term "light chain (LC)" refers to a full-length light chain and fragments thereof comprising a variable region domain VL and a constant region domain CL, wherein VL comprises an amino acid sequence of sufficient variable region sequence to confer antigen specificity.
[0067] As used herein, the term "variable" means that a particular portion of the variable region has significant differences in sequence between antibodies. The V region mediates antigen binding and determines the specificity of a particular antibody for its specific antigen. The variability is concentrated in three segments called hypervariable regions (HVRs), namely the CDRs of the light and heavy chain variable regions. The highly conserved portions of the variable regions are called framework (FR) regions. The heavy and light chain variable regions have FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4 structures from N-terminal to C-terminal.
[0068] As used herein, the term "CDR (complementarity determining region)" refers to the amino acid sequence of the hypervariable region of the heavy and light chains of immunoglobulins. Both the heavy chain (HCDR1, HCDR2 and HCDR3) and the light chain (LCDR1, LCDR2 and LCDR3) contain three CDRs. CDR provides key contact residues for the binding of antibodies to antigens or epitopes.
[0069] As used herein, the term "substituted with another amino acid" refers to replacement with another amino acid residue having similar properties to the original amino acid sequence. As long as the properties of the antibody of the present disclosure can be maintained even if amino acid substitution occurs, there is no particular limitation. The "amino acid" introduced by the above substitution can be selected from any one of lysine (K), alanine (A), arginine (R), asparagine (N), aspartic acid (D), cysteine (C), glutamine (Q), glutamic acid (E), glycine (G), histidine (H), isoleucine (I), leucine (L), methionine (M), phenylalanine (F), proline (P), serine (S), threonine (T), tryptophan (W), tyrosine (Y) and valine (V). The substitution can be described as, for example, "N3 amino acid in the amino acid sequence shown in SEQ ID NO:1", referring to N at position 3 of SEQ ID NO:1.
[0070] In some embodiments, the N3 amino acid in the amino acid sequence shown in SEQ ID NO: 1 can be substituted with Ser (S) or Gln (Q), but is not limited thereto.
[0071] In some embodiments, the C2 amino acid in the amino acid sequence shown in SEQ ID NO: 5 may be substituted with Ser (S) or Tyr (Y), but is not limited thereto.
[0072] In some embodiments, variant No.1 may include a light chain variable region, the light chain variable region including LCDR1 having an amino acid sequence as shown in SEQ ID NO:9, LCDR2 having an amino acid sequence as shown in SEQ ID NO:2, and LCDR3 having an amino acid sequence as shown in SEQ ID NO:3; and a heavy chain variable region, the heavy chain variable region including HCDR1 having an amino acid sequence as shown in SEQ ID NO:11, HCDR2 having an amino acid sequence as shown in SEQ ID NO:6, and HCDR3 having an amino acid sequence as shown in SEQ ID NO:7. In this regard, the Fc region of the antibody may be IgG1 or a variant thereof, IgG4 or a variant thereof. Variant No.1 may be represented as HL161ANS, HL161ANS (IgG1null), or HL161ANS (IgG4).
[0073] In some embodiments, variant No. 12 may include a light chain variable region, the light chain variable region including LCDR1 having an amino acid sequence as shown in SEQ ID NO: 13, LCDR2 having an amino acid sequence as shown in SEQ ID NO: 2, and LCDR3 having an amino acid sequence as shown in SEQ ID NO: 3; and a heavy chain variable region, the heavy chain variable region including HCDR1 having an amino acid sequence as shown in SEQ ID NO: 11, HCDR2 having an amino acid sequence as shown in SEQ ID NO: 6, and HCDR3 having an amino acid sequence as shown in SEQ ID NO: 7. In this regard, the Fc region of the antibody may be IgG1 or a variant thereof, IgG4 or a variant thereof. Variant No. 12 may be represented as HL161ANQ, HL161ANQ (IgG1null), or HL161ANQ (IgG4).
[0074] In some embodiments, variant No.2 may include a light chain variable region, the light chain variable region including LCDR1 having an amino acid substitution of N3 to Ser (S) in the amino acid sequence shown in SEQ ID NO: 1, LCDR2 having an amino acid sequence shown in SEQ ID NO: 2, and LCDR3 having an amino acid sequence shown in SEQ ID NO: 3; and a heavy chain variable region, the heavy chain variable region including HCDR1 having an amino acid substitution of C2 to Tyr (Y) in the amino acid sequence shown in SEQ ID NO: 5, HCDR2 having an amino acid sequence shown in SEQ ID NO: 6, and HCDR3 having an amino acid sequence shown in SEQ ID NO: 7. In this regard, the Fc region of the antibody may be IgG1 or a variant thereof, IgG4 or a variant thereof. Variant No.2 may be represented as HL161ANSY, HL161ANSY (IgG1null), or HL161ANSY (IgG4).
[0075] In some embodiments, variant No. 13 may include a light chain variable region, the light chain variable region including LCDR1 having an amino acid substitution of N3 to Gln (Q) in the amino acid sequence shown in SEQ ID NO: 1, LCDR2 having an amino acid sequence shown in SEQ ID NO: 2, and LCDR3 having an amino acid sequence shown in SEQ ID NO: 3; and a heavy chain variable region, the heavy chain variable region including HCDR1 having an amino acid substitution of C2 to Tyr (Y) in the amino acid sequence shown in SEQ ID NO: 5, HCDR2 having an amino acid sequence shown in SEQ ID NO: 6, and HCDR3 having an amino acid sequence shown in SEQ ID NO: 7. In this regard, the Fc region of the antibody may be IgG1 or a variant thereof, IgG4 or a variant thereof. Variant No. 13 may be represented as HL161ANQY, HL161ANQY (IgG1null), or HL161ANQY (IgG4).
[0076] In some embodiments, variant No. 23 may include a light chain variable region, the light chain variable region including LCDR1 having an amino acid substitution of N3 to Ser (S) in the amino acid sequence shown in SEQ ID NO: 1, LCDR2 having an amino acid sequence shown in SEQ ID NO: 2, and LCDR3 having an amino acid sequence shown in SEQ ID NO: 3; and a heavy chain variable region, the heavy chain variable region including HCDR1 having an amino acid substitution of C2 to Tyr (Y) in the amino acid sequence shown in SEQ ID NO: 5, HCDR2 having an amino acid sequence shown in SEQ ID NO: 6, and HCDR3 having an amino acid sequence shown in SEQ ID NO: 7. In this regard, the Fc region of the antibody may be IgG1 or a variant thereof, IgG4 or a variant thereof. Variant No. 23 may be represented as HL161ANSY, HL161ANSY (IgG1null), or HL161ANSY (IgG4).
[0077] In some embodiments, the anti-FcRn antibody or antigen-binding fragment thereof comprises a VL CDR1 having the sequence GGX1NIGSTSV (SEQ ID NO: 38), wherein X1 is N, S, or Q. In some embodiments, the anti-FcRn antibody or antigen-binding fragment thereof comprises a VH CDR1 having the sequence SX2VMT (SEQ ID NO: 39), wherein X2 is C, S, or Y.
[0078] In some embodiments, the heavy chain variable region of the anti-FcRn antibody or antigen-binding fragment thereof may comprise a framework consisting of FR1 as shown in the amino acid sequence of SEQ ID NO: 15, FR2 as shown in the amino acid sequence of SEQ ID NO: 16, FR3 as shown in the amino acid sequence of SEQ ID NO: 17, and FR4 as shown in the amino acid sequence of SEQ ID NO: 18.
[0079] In the framework FR3 of the heavy chain variable region, a specific amino acid may be substituted with another amino acid, but is not limited thereto. Specifically, the Q16 amino acid in the amino acid sequence shown in SEQ ID NO: 17 is substituted with another amino acid.
[0080] As described above, even if an amino acid substitution occurs, as long as the properties of the antibody according to the present disclosure are maintained, the above-mentioned “substitution with another amino acid” is not particularly limited.
[0081] In one embodiment, the Q16 amino acid in the amino acid sequence shown in SEQ ID NO: 17 can be substituted with Glu (E).
[0082] In one embodiment, variant No. 8 comprises a light chain variable region, the light chain variable region comprising LCDR1 having an amino acid sequence as shown in SEQ ID NO: 9, LCDR2 having an amino acid sequence as shown in SEQ ID NO: 2, and LCDR3 having an amino acid sequence as shown in SEQ ID NO: 3; and a heavy chain variable region, the heavy chain variable region comprising HCDR1 having an amino acid sequence as shown in SEQ ID NO: 11, HCDR2 having an amino acid sequence as shown in SEQ ID NO: 6, and HCDR3 having an amino acid sequence as shown in SEQ ID NO: 7, wherein the amino acid sequence may include FR3 in which the amino acid Q16 is substituted with Glu (E) in the amino acid sequence as shown in SEQ ID NO: 17. In this regard, the Fc region of the antibody may be IgG1 or a variant thereof, IgG4 or a variant thereof. Variant No. 8 may be represented as HL161ANSE, HL161ANSE (IgG1null), or HL161ANSE (IgG4).
[0083] In one embodiment, variant No. 19 comprises a light chain variable region, the light chain variable region comprising LCDR1 having an amino acid sequence as shown in SEQ ID NO: 13, LCDR2 having an amino acid sequence as shown in SEQ ID NO: 2, and LCDR3 having an amino acid sequence as shown in SEQ ID NO: 3; and a heavy chain variable region, the heavy chain variable region comprising HCDR1 having an amino acid sequence as shown in SEQ ID NO: 11, HCDR2 having an amino acid sequence as shown in SEQ ID NO: 6, and HCDR3 having an amino acid sequence as shown in SEQ ID NO: 7, wherein the amino acid sequence may include FR3 in which the amino acid Q16 in the amino acid sequence as shown in SEQ ID NO: 17 is substituted with Glu (E). In this regard, the Fc region of the antibody may be IgG1 or a variant thereof, IgG4 or a variant thereof. Variant No. 19 may be represented as HL161ANQE, HL161ANQE (IgG1null), or HL161ANQE (IgG4).
[0084] In one embodiment, variant No.11 comprises a light chain variable region, the light chain variable region comprising LCDR1 having an amino acid substitution of N3 to Ser (S) in the amino acid sequence shown in SEQ ID NO:1, LCDR2 having an amino acid sequence shown in SEQ ID NO:2, and LCDR3 having an amino acid sequence shown in SEQ ID NO:3; and a heavy chain variable region, the heavy chain variable region comprising HCDR1 having an amino acid substitution of C2 to Tyr (Y) in the amino acid sequence shown in SEQ ID NO:5, HCDR2 having an amino acid sequence shown in SEQ ID NO:6, and HCDR3 having an amino acid sequence shown in SEQ ID NO:7, wherein the amino acid sequence may comprise FR3 having an amino acid substitution of Q16 to Glu (E) in the amino acid sequence shown in SEQ ID NO:17. In this regard, the Fc region of the antibody may be IgG1 or a variant thereof, IgG4 or a variant thereof. Variant No.11 may be represented as HL161ANSYE, HL161ANSYE (IgG1null), or HL161ANSYE (IgG4).
[0085] In one embodiment, variant No. 22 comprises a light chain variable region, the light chain variable region comprising LCDR1 having an amino acid substitution of N3 to Gln (Q) in the amino acid sequence shown in SEQ ID NO: 1, LCDR2 having an amino acid sequence shown in SEQ ID NO: 2, and LCDR3 having an amino acid sequence shown in SEQ ID NO: 3; and a heavy chain variable region, the heavy chain variable region comprising HCDR1 having an amino acid substitution of C2 to Tyr (Y) in the amino acid sequence shown in SEQ ID NO: 5, HCDR2 having an amino acid sequence shown in SEQ ID NO: 6, and HCDR3 having an amino acid sequence shown in SEQ ID NO: 7, wherein the amino acid sequence may comprise FR3 having an amino acid substitution of Q16 to Glu (E) in the amino acid sequence shown in SEQ ID NO: 17. In this regard, the Fc region of the antibody may be IgG1 or a variant thereof, IgG4 or a variant thereof. Variant No. 11 may be represented as HL161ANQYE, HL161ANQYE (IgG1null), or HL161ANQYE (IgG4).
[0086] In another aspect of the present disclosure, provided is an anti-FcRn antibody or an antigen-binding fragment thereof, comprising a light chain variable region having an amino acid sequence as shown in SEQ ID NO:4 and a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:8.
[0087] In this regard, in the anti-FcRn antibody or antigen-binding fragment thereof, the N25 amino acid in the amino acid sequence shown in SEQ ID NO:4 may be substituted with another amino acid, and the C32 or Q82 amino acid in the amino acid sequence shown in SEQ ID NO:8 may be substituted with another amino acid.
[0088] The “anti-FcRn antibody”, “antigen-binding fragment” and “substituted with another amino acid” are as described above.
[0089] In one embodiment, the N25 amino acid in the amino acid sequence shown in SEQ ID NO: 4 can be substituted with Ser (S) or Gln (Q), but is not limited thereto.
[0090] In one embodiment, the C32 amino acid in the amino acid sequence shown in SEQ ID NO: 8 can be substituted with Ser (S) or Tyr (Y), but is not limited thereto.
[0091] In one embodiment, the amino acid Q82 in the amino acid sequence shown in SEQ ID NO: 8 may be substituted with Glu (E), but is not limited thereto.
[0092] In one embodiment, variant No. 1 may comprise a light chain variable region having an amino acid sequence as shown in SEQ ID NO: 10, and a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO: 12. In this regard, the Fc region of the antibody may be IgG1 or a variant thereof, IgG4 or a variant thereof.
[0093] In one embodiment, variant No. 12 may comprise a light chain variable region having an amino acid sequence as shown in SEQ ID NO: 14, and a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO: 12. In this regard, the Fc region of the antibody may be IgG1 or a variant thereof, IgG4 or a variant thereof.
[0094] In one embodiment, variant No. 2 may comprise a light chain variable region having an amino acid sequence as shown in SEQ ID NO: 10, and a heavy chain variable region having an amino acid sequence in which the C32 amino acid in the amino acid sequence as shown in SEQ ID NO: 8 is substituted with Tyr (Y). In this regard, the Fc region of the antibody may be IgG1 or a variant thereof, IgG4 or a variant thereof.
[0095] In one embodiment, variant No. 13 may comprise a light chain variable region having an amino acid sequence as shown in SEQ ID NO: 14, and a heavy chain variable region having an amino acid sequence in which the C32 amino acid in the amino acid sequence as shown in SEQ ID NO: 8 is substituted with Tyr (Y). In this regard, the Fc region of the antibody may be IgG1 or a variant thereof, IgG4 or a variant thereof.
[0096] In one embodiment, variant No. 8 may comprise a light chain variable region having an amino acid sequence as shown in SEQ ID NO: 10, and a heavy chain variable region having an amino acid sequence in which the amino acid C32 in the amino acid sequence as shown in SEQ ID NO: 8 is substituted with Ser (S) and the amino acid Q82 is substituted with Glu (E). In this regard, the Fc region of the antibody may be IgG1 or a variant thereof, IgG4 or a variant thereof.
[0097] In one embodiment, variant No. 19 may comprise a light chain variable region having an amino acid sequence as shown in SEQ ID NO: 14, and a heavy chain variable region having an amino acid sequence in which the amino acid C32 in the amino acid sequence as shown in SEQ ID NO: 8 is substituted with Ser (S) and the amino acid Q82 is substituted with Glu (E). In this regard, the Fc region of the antibody may be IgG1 or a variant thereof, IgG4 or a variant thereof.
[0098] In one embodiment, variant No. 11 may comprise a light chain variable region having an amino acid sequence as shown in SEQ ID NO: 10, and a heavy chain variable region having an amino acid sequence in which the amino acid at C32 in the amino acid sequence as shown in SEQ ID NO: 8 is substituted with Tyr (Y) and the amino acid at Q82 is substituted with Glu (E). In this regard, the Fc region of the antibody may be IgG1 or a variant thereof, IgG4 or a variant thereof.
[0099] In one embodiment, variant No. 22 may comprise a light chain variable region having an amino acid sequence as shown in SEQ ID NO: 14, and a heavy chain variable region having an amino acid sequence in which the amino acid at C32 in the amino acid sequence as shown in SEQ ID NO: 8 is substituted with Tyr (Y) and the amino acid at Q82 is substituted with Glu (E). In this regard, the Fc region of the antibody may be IgG1 or a variant thereof, IgG4 or a variant thereof.
[0100] In some embodiments, the anti-FcRn antibody comprises a light chain variable region having a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the sequence shown in SEQ ID NO: 4. In some of these embodiments, the CDR sequence of the light chain variable region is 100% identical to SEQ ID NO: 4. In some embodiments, the anti-FcRn antibody comprises a light chain variable region having a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the sequence shown in SEQ ID NO: 10. In some of these embodiments, the CDR sequence of the light chain variable region is 100% identical to SEQ ID NO: 10. In some embodiments, the anti-FcRn antibody comprises a light chain variable region having a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the sequence shown in SEQ ID NO: 14. In some of these embodiments, the CDR sequences of the light chain variable region are 100% identical to SEQ ID NO: 14.
[0101] In some embodiments, the anti-FcRn antibody comprises a heavy chain variable region having a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the sequence shown in SEQ ID NO: 8. In some of these embodiments, the CDR sequence of the heavy chain variable region is 100% identical to SEQ ID NO: 8. In some embodiments, the anti-FcRn antibody comprises a heavy chain variable region having a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the sequence shown in SEQ ID NO: 12. In some of these embodiments, the CDR sequence of the heavy chain variable region is 100% identical to SEQ ID NO: 12.
[0102] In some embodiments, the anti-FcRn antibody comprises any of the CDRs, light chain variable regions, and / or heavy chain variable regions described herein, and further comprises an IgG1-Fc region. In some embodiments, the anti-FcRn antibody comprises any of the CDRs, light chain variable regions, and / or heavy chain variable regions described herein, and further comprises an IgG1 Fc region comprising a Leu234Ala / Leu235Ala ("LALA") amino acid substitution ("IgG1 LALA").
[0103] In some embodiments, the anti-FcRn antibody comprises any of the CDRs, light chain variable regions, and / or heavy chain variable regions described herein, and further comprises an IgG4 Fc region. In some embodiments, the anti-FcRn antibody comprises any of the CDRs, light chain variable regions, and / or heavy chain variable regions described herein, and further comprises an IgG1 Fc region comprising an S228P amino acid substitution ("IgG4 S228P").
[0104] In some embodiments, the anti-FcRn antibody is an IgG1 antibody and comprises a light chain variable region comprising a LCDR1 having an amino acid sequence as shown in SEQ ID NO:9, a LCDR2 having an amino acid sequence as shown in SEQ ID NO:2, and a LCDR3 having an amino acid sequence as shown in SEQ ID NO:3; and a heavy chain variable region comprising a HCDR1 having an amino acid sequence as shown in SEQ ID NO:11, a HCDR2 having an amino acid sequence as shown in SEQ ID NO:6, and a HCDR3 having an amino acid sequence as shown in SEQ ID NO:7. In some embodiments, the anti-FcRn antibody is an IgG4 antibody and comprises a light chain variable region comprising a LCDR1 having an amino acid sequence as shown in SEQ ID NO:9, a LCDR2 having an amino acid sequence as shown in SEQ ID NO:2, and a LCDR3 having an amino acid sequence as shown in SEQ ID NO:3; and a heavy chain variable region comprising a HCDR1 having an amino acid sequence as shown in SEQ ID NO:11, a HCDR2 having an amino acid sequence as shown in SEQ ID NO:6, and a HCDR3 having an amino acid sequence as shown in SEQ ID NO:7.
[0105] In some embodiments, the anti-FcRn antibody is an IgG1-LALA antibody and comprises a light chain variable region comprising LCDR1 having the amino acid sequence shown in SEQ ID NO:9, LCDR2 having the amino acid sequence shown in SEQ ID NO:2, and LCDR3 having the amino acid sequence shown in SEQ ID NO:3; and a heavy chain variable region comprising HCDR1 having the amino acid sequence shown in SEQ ID NO:11, HCDR2 having the amino acid sequence shown in SEQ ID NO:6, and HCDR3 having the amino acid sequence shown in SEQ ID NO:7. In some embodiments, the anti-FcRn antibody is an IgG4 S228P antibody and comprises a light chain variable region comprising a LCDR1 having an amino acid sequence as shown in SEQ ID NO:9, a LCDR2 having an amino acid sequence as shown in SEQ ID NO:2, and a LCDR3 having an amino acid sequence as shown in SEQ ID NO:3; and a heavy chain variable region comprising a HCDR1 having an amino acid sequence as shown in SEQ ID NO:11, a HCDR2 having an amino acid sequence as shown in SEQ ID NO:6, and a HCDR3 having an amino acid sequence as shown in SEQ ID NO:7.
[0106] In one embodiment, HL161ANS (IgG1null) may comprise a light chain region having an amino acid sequence as shown in SEQ ID NO:21 and a heavy chain region having an amino acid sequence as shown in SEQ ID NO:22.
[0107] In one embodiment, HL161ANS (IgG4) may comprise a light chain region having an amino acid sequence as shown in SEQ ID NO:21 and a heavy chain region having an amino acid sequence as shown in SEQ ID NO:23.
[0108] In one embodiment, HL161ANQ (IgG1null) may comprise a light chain region having an amino acid sequence as shown in SEQ ID NO:24 and a heavy chain region having an amino acid sequence as shown in SEQ ID NO:22.
[0109] In one embodiment, HL161ANQ (IgG4) may comprise a light chain region having an amino acid sequence as shown in SEQ ID NO:24 and a heavy chain region having an amino acid sequence as shown in SEQ ID NO:23.
[0110] In one embodiment, HL161ANSY(IgG1null) may comprise a light chain region having an amino acid sequence as shown in SEQ ID NO:21 and a heavy chain region having an amino acid sequence as shown in SEQ ID NO:25.
[0111] In one embodiment, HL161ANSE (IgG1null) may comprise a light chain region having an amino acid sequence as shown in SEQ ID NO:21 and a heavy chain region having an amino acid sequence as shown in SEQ ID NO:26.
[0112] In one embodiment, HL161ANSYE(IgG1null) may comprise a light chain region having an amino acid sequence as shown in SEQ ID NO:21 and a heavy chain region having an amino acid sequence as shown in SEQ ID NO:27.
[0113] In one embodiment, HL161ANQY(IgG1null) may comprise a light chain region having an amino acid sequence as shown in SEQ ID NO:24 and a heavy chain region having an amino acid sequence as shown in SEQ ID NO:25.
[0114] In one embodiment, HL161ANQE (IgG1null) may comprise a light chain region having an amino acid sequence as shown in SEQ ID NO:24 and a heavy chain region having an amino acid sequence as shown in SEQ ID NO:26.
[0115] In one embodiment, HL161ANQYE(IgG1null) may comprise a light chain region having an amino acid sequence as shown in SEQ ID NO:24 and a heavy chain region having an amino acid sequence as shown in SEQ ID NO:27.
[0116] In one embodiment, the anti-FcRn antibody is an anti-FcR antibody variant prepared by replacing amino acid residues at specific sites of the parent antibody HL161AN, and it is confirmed that it has a reduced aggregate production rate while maintaining high affinity and specificity for FcR like the parent antibody. In one embodiment, the anti-FcRn antibody is an anti-FcR antibody variant prepared by replacing amino acid residues at specific sites of the parent antibody HL161AN, and it is confirmed that it has a reduced aggregate production rate while maintaining high affinity for FcRn like the parent antibody. Specifically, it is confirmed that the anti-FcRn antibody variant according to the present disclosure has improved stability, such as a reduction in the production rate of aggregates by two times or more, while having excellent biological activities, such as the previously developed parent antibody HL161AN (Korean Patent No. 10-1954906), such as productivity, an effect as an inhibitor of IgG and FcRn binding, and an IgG catabolism effect, i.e., promoting IgG clearance.
[0117] Therefore, the anti-FcRn antibody variants according to the present disclosure can be effectively used to treat autoimmune diseases, the variants having significantly improved stability while having excellent biological activities similar to the previously developed parent antibody HL161AN.
[0118] In some embodiments, administration of an anti-FcR antibody described herein to a subject reduces blood immunoglobulin levels (e.g., IgG levels) in the subject by at least 30%, 40%, 50%, 60%, 65%, or 80% compared to the subject's blood immunoglobulin levels (e.g., IgG levels) prior to administration of the anti-FcRn antibody.
[0119] In some embodiments, when administered to a subject, the anti-FcRn antibodies described herein cause the immunoglobulin levels (e.g., IgG levels) in the subject's blood to be lower than another anti-FcR antibody. In some embodiments, the anti-FcRn antibodies described herein cause the immunoglobulin levels (e.g., IgG levels) in the subject's blood to be lower than batoclimab. In some embodiments, administering the anti-FcRn antibodies described herein to a subject reduces the immunoglobulin levels (e.g., IgG levels) in the subject's blood to a level approximately the same as administering a comparable dose of batoclimab. Batoclimab is known in the art and is also described, for example, in International Patent Application Publication No. WO2015 / 167293, the entire contents of which are incorporated herein by reference; batoclimab is referred to as "HL161BKN" in WO2015 / 167293.
[0120] In some embodiments, administration of an effective amount of an anti-FcRn antibody described herein to a subject (e.g., a human) reduces blood albumin levels by less than 5%, less than 10%, less than 20%, or less than 30% compared to blood albumin levels before administration. In some embodiments, administration of an effective amount of an anti-FcRn antibody described herein to a subject (e.g., a human) increases blood cholesterol levels by less than 5%, less than 10%, less than 20%, or less than 30% compared to blood cholesterol levels before administration.
[0121] In some embodiments, administration of an effective amount of an anti-FcRn antibody described herein to a subject (e.g., a human) increases total blood cholesterol levels by less than 5%, less than 10%, less than 20%, or less than 30%, compared to total blood cholesterol levels before administration.
[0122] In some embodiments, administration of an effective amount of an anti-FcRn antibody described herein to a subject (e.g., a human) increases blood LDL levels by less than 5%, less than 10%, less than 20%, or less than 30% compared to blood LDL levels before administration.
[0123] In some embodiments, administration of an effective amount of an anti-FcRn antibody described herein to a subject (e.g., a human) reduces blood immunoglobulin levels by at least about 40%, 50%, 65% or 80%, but has (i) no or minimal effect on blood albumin levels (e.g., reduces blood albumin by less than 20%, 10%, less than 5%, less than 2% or less than 1%) and / or (ii) no or minimal effect on blood total cholesterol levels and / or LDL levels (e.g., increases cholesterol by less than 20%, 10%, less than 5%, less than 2% or less than 1%) compared to levels before administration.
[0124] In some embodiments, administration of an effective amount of an anti-FcRn antibody described herein to a subject (e.g., a human) reduces blood immunoglobulin levels by at least about 40%, 50%, 65%, or 80%, compared to pre-administration levels, but has no or only a small effect on blood albumin levels (e.g., reduces blood albumin by less than 10%, less than 5%, less than 2%, or less than 1%), and has no or only a minimal effect on blood cholesterol (i.e., increases cholesterol by less than 10%, greater than 5%, less than 2%, or less than 1%).
[0125] In some embodiments, subcutaneous administration of an effective amount of an anti-FcRn antibody described herein to a human subject (e.g., chronic subcutaneous administration to a human) can reduce blood immunoglobulin levels by at least about 40%, 50%, 65% or 80% compared to pre-administration levels, but has little or no effect on blood albumin levels (e.g., reduces blood albumin by less than 10%, less than 5%, less than 2% or less than 1%), and has little or no effect on blood cholesterol (e.g., increases cholesterol by less than 10%, less than 5%, less than 2% or less than 1%).
[0126] In some embodiments, administration of an effective amount of an anti-FcRn antibody described herein to a subject (e.g., a human) reduces blood immunoglobulin levels by at least about 40%, 50%, 65%, or 80%, but has no or minimal effect on blood albumin levels (e.g., reduces blood albumin by less than 10%, less than 5%, less than 2%, or less than 1%), and has no or minimal effect on blood LDL levels (e.g., increases LDL by less than 10%, greater than 5%, less than 2%, or less than 1%), compared to pre-administration levels.
[0127] In some embodiments, subcutaneous administration of an effective amount of an anti-FcRn antibody described herein to a human subject (e.g., chronic subcutaneous administration to a human) reduces blood immunoglobulin levels by at least about 40%, 50%, 65%, or 80%, compared to pre-administration levels, but has no effect or minimal effect on blood albumin levels (e.g., reduces blood albumin by less than 10%, less than 5%, less than 2%, or less than 1%), and has no effect or minimal effect on blood LDL levels (e.g., increases LDL by less than 10%, less than 5%, less than 2%, or less than 1%).
[0128] In some embodiments, chronic subcutaneous administration of an effective amount of an anti-FcRn antibody described herein to a human for 12 weeks or longer reduces blood immunoglobulin levels by at least about 40%, 50%, 65%, or 80%, compared to pre-administration levels, but has no or minimal effect on blood albumin levels (e.g., reduces blood albumin by less than 10%, less than 5%, less than 2%, or less than 1%), and has no or minimal effect on blood LDL and / or cholesterol levels (e.g., increases LDL and / or cholesterol by less than 10%, less than 5%, less than 2%, or less than 1%).
[0129] Functional variants of the antibodies or antigen-binding fragments described herein are also encompassed in the present invention. The term "functional variant" as used herein includes modifications or chemical equivalents of amino acids and nucleic acid sequences disclosed herein, which perform substantially the same functions as polypeptides or nucleic acid molecules disclosed herein in substantially the same manner. For example, functional variants of polypeptides disclosed herein include, but are not limited to, conservative amino acid substitutions. "Conservative amino acid substitutions" as used herein are substitutions in which one amino acid residue is substituted by another amino acid residue, which is a substitution that changes an amino acid into a different amino acid with similar biochemical properties (e.g., charge, hydrophobicity, and size). For example, lysine, arginine, and histidine have similar properties because they have basic side chains, while aspartic acid and glutamic acid have similar properties because they have acidic side chains. In addition, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, and tryptophan have similar properties because they have uncharged polar side chains, while alanine, valine, leucine, threonine, isoleucine, proline, phenylalanine, and methionine have similar properties because they have non-polar side chains. In addition, tyrosine, phenylalanine, tryptophan and histidine have similar properties because they have aromatic side chains. Therefore, it is obvious to those skilled in the art that even when the amino acid residues in the group showing similar properties as above are substituted, the properties will not show special changes. Variants of polypeptides also include additions and deletions to the polypeptide sequences disclosed herein. In addition, variant nucleotide sequences include analogs and derivatives thereof. Variants of binding proteins disclosed herein include proteins that bind to the same antigen or epitope as the antigen or epitope to which the binding protein binds.
[0130] Since the C-terminal lysine of the immunoglobulin heavy chain may be cleaved during the production process, it is obvious to those skilled in the art. Therefore, in some embodiments, the antibodies described herein comprise two C-terminal lysine residues (i.e., there is one C-terminal lysine on each heavy chain). In some embodiments, the antibodies described herein comprise one C-terminal lysine residue (i.e., there is a C-terminal lysine on one heavy chain, and there is no C-terminal lysine on the other heavy chain). In some embodiments, the antibodies described herein do not comprise a C-terminal lysine residue on any heavy chain.
[0131] It is desirable to modify the antibodies disclosed herein according to effector functions to enhance, for example, the effectiveness of antibodies in treating related diseases and disorders. For example, cysteine residues can be introduced into the Fc region, thereby allowing the formation of interchain disulfide bonds in the region. The homodimeric antibodies thus produced have improved internalization capacity and / or increased complement-mediated cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC). (See Caron et al., J Exp Med., 176: 1191-1195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992)). Alternatively, the antibody can be engineered to have dual Fc regions, thereby having enhanced complement cell lysis and ADCC capabilities. (See Stevenson et al., Anti-Cancer Drug Design, 3: 219-230 (1989)). Mutations affecting antibody effector function are well known in the art, see, for example, Saunders et al., 2019; Front. Immunol. 10: 1296 and Wang et al., 2018, Protein Cell 9 (1): 63-73, the entire contents of each of which are incorporated herein by reference, and can be used as examples to introduce Fc modifications in antibodies described herein. Unless otherwise indicated, the Fc mutations in this section are described with reference to the Kabat numbering scheme for immunoglobulins. Exemplary mutations and combinations of mutations that can be introduced into the Fc of the anti-FcRn antibodies provided herein include, but are not limited to, Lys326Trp / Glu333Ser, Ser267Glu / His268Phe / Ser324Thr, Lys326Trp / Glu333Ser, Lys326Ala / Glu333Ala, Lys326Met / Glu333Ser, Cys221Asp / Asp222Cys, Ser267Glu, His268Phe, Ser324Thr, Glu345Arg, S239D / I332E, S239D / I332E / A330L , Arg435His, Met252Tyr / Ser254Thr / Thr256Glu (“YTE”), Met428Leu / Asn434Ser, Thr252Leu / Thr253Ser / Thr254Phe, Leu235Glu, Leu234Ala / Leu235Ala ("LALA"), Ser228Pro / Leu235Glu, Leu234Ala / Leu235Ala / Pro329Gly, Pro331Ser / Leu234Glu / Leu235Phe, Asp265Ala and Ala330Leu.
[0132] In some embodiments, the anti-FcRn antibody is an IgG1 antibody comprising a Leu234Ala / Leu235Ala ("LALA") mutation (ie, an "IgG1-LALA" antibody). In some embodiments, the anti-FcRn antibody is an IgG4 antibody comprising a S228P mutation (ie, an "IgG4 S228P" antibody).
[0133] Polynucleotides encoding anti-FcRn antibody variants
[0134] In another aspect of the present invention, a polynucleotide encoding an anti-FcRn antibody or an antigen-binding fragment thereof is provided.
[0135] Specifically, the polynucleotide encoding the heavy chain may comprise the sequence of SEQ ID NO: 31, 33, 35 or 37. In addition, the polynucleotide encoding the light chain may comprise the sequence of SEQ ID NO: 30, 32, 34 or 36.
[0136] The polynucleotide may comprise a nucleic acid sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% identical to SEQ ID NO:30, 31, 32, 33, 34, 35, 36 or 37.
[0137] In some embodiments, the polynucleotide comprises the sequence of SEQ ID NO: 30. In some embodiments, the polynucleotide comprises the sequence of SEQ ID NO: 31. In some embodiments, the polynucleotide comprises the sequence of SEQ ID NO: 30 and SEQ ID NO: 31. In some embodiments, the polynucleotide comprises the sequence of SEQ ID NO: 32. In some embodiments, the polynucleotide comprises the sequence of SEQ ID NO: 33. In some embodiments, the polynucleotide comprises the sequence of SEQ ID NO: 32 and SEQ ID NO: 33.
[0138] The polynucleotide can be mutated by substitution, deletion, insertion of one or more bases or a combination thereof. When the nucleotide sequence is prepared by chemical synthesis, synthetic methods known in the art can be used, such as the method described in document (Engels and Uhlmann, Angew Chem Int Ed Engl., 37: 73-127, 1988), and can include triesters, phosphites, phosphoramidites and H-phosphoester methods, PCR and other automatic primers (autoprimer) methods, oligonucleotide synthesis methods on solid supports, etc.
[0139] Vectors carrying polynucleotides encoding anti-FcRn antibody variants
[0140] In another aspect of the present invention, a recombinant expression vector comprising the polynucleotide is provided.
[0141] Furthermore, the polynucleotide may have the heavy chain and the light chain loaded into one vector, or the heavy chain and the light chain loaded into two vectors, respectively.
[0142] Specifically, when loaded into a vector, the polynucleotide may include a polynucleotide of SEQ ID NO:30 and a polynucleotide of SEQ ID NO:31; a polynucleotide of SEQ ID NO:32 and a polynucleotide of SEQ ID NO:33; a polynucleotide of SEQ ID NO:34 and a polynucleotide of SEQ ID NO:35; or a polynucleotide of SEQ ID NO:36 and a polynucleotide of SEQ ID NO:37.
[0143] The vectors provided herein may comprise a polynucleotide encoding a light chain of an anti-FcRn antibody or an antigen-binding fragment thereof and / or a heavy chain of an anti-FcRn antibody or an antigen-binding fragment thereof.
[0144] In some embodiments, the vector comprises a polynucleotide comprising the sequence of SEQ ID NO: 30. In some embodiments, the vector comprises a polynucleotide comprising the sequence of SEQ ID NO: 31. In some embodiments, the vector comprises a polynucleotide comprising the sequence of SEQ ID NO: 30 (encoding the light chain) and the sequence of SEQ ID NO: 31 (encoding the heavy chain).
[0145] In some embodiments, the vector comprises a polynucleotide comprising the sequence of SEQ ID NO: 32. In some embodiments, the vector comprises a polynucleotide comprising the sequence of SEQ ID NO: 33. In some embodiments, the vector comprises a polynucleotide comprising the sequence of SEQ ID NO: 32 (encoding the light chain) and the sequence of SEQ ID NO: 33 (encoding the heavy chain).
[0146] The vector can be introduced into a host cell and recombined and inserted into the host cell genome. Alternatively, the vector should be understood as a "nucleic acid" containing a polynucleotide sequence that can replicate spontaneously in the form of an episome. The vector includes linear nucleic acids, plasmids, phagemids, cosmids, RNA vectors, viral vectors and the like. Examples of viral vectors include retroviruses, adenoviruses, and adeno-associated viruses, but are not limited thereto.
[0147] Specifically, the vector may be plasmid DNA, phage DNA, etc. In addition, it may be a commercially developed plasmid (pUC18, pBAD, pIDTSAMRT-AMP, etc.), a plasmid derived from Escherichia coli (pYG601BR322, pBR325, pUC118, pUC119, etc.), a plasmid derived from Bacillus subtilis (pUB110, pTP5, etc.), a plasmid derived from yeast (YEp13, YEp24, YCp50, etc.), a phage DNA (Charon4A, Charon21A, EMBL3, EMBL4, λgt10, λgt11, λZAP, etc.), an animal virus vector (retrovirus, adenovirus, vaccinia virus, etc.), an insect virus vector (baculovirus, etc.). Since the vector shows different protein expression levels and modifications depending on the host cell, it is preferred to select and use the most suitable host cell for the purpose.
[0148] The vector of the present invention can be fused with other sequences to facilitate purification of antibodies expressed therefrom. The sequences to be fused include, for example, glutathione S-transferase (Pharmacia, USA), maltose binding protein (NEB, USA), FLAG (IBI, USA), 6×His (six histidine; Quiagen, USA), etc.
[0149] In addition, since the protein expressed by the vector of the present invention is an antibody, the expressed antibody can be easily purified by a Protein A column or the like without requiring an additional sequence for purification.
[0150] Transformed cells expressing anti-FcRn antibody variants
[0151] In another aspect of the present invention, a host cell transformed with the recombinant expression vector is provided.
[0152] The host cell of the transformed cell may include prokaryotic cells, eukaryotic cells, mammals, plants, insects, fungi or cells of cell origin, but is not limited thereto. Escherichia coli can be used as an example of a prokaryotic cell. In addition, yeast can be used as an example of a eukaryotic cell. In addition, the following cells can be used as examples of mammalian cells, but are not limited thereto: CHO cells, F2N cells, CSO cells, BHK cells, Bowes melanoma cells, HeLa cells, 911 cells, AT1080 cells, A549 cells, HEK293 cells, HEK293T cells, etc., and any cell known to those skilled in the art that can be used as a mammalian host cell.
[0153] In the present disclosure, "transformation" or "transfection" into a host cell includes any method for introducing nucleic acid into an organism, cell, tissue or organ, and as is well known in the art, a suitable standard technique can be selected and performed according to the host cell. For example, the CaCl2 precipitation method, the Hanahan method using DMSO (dimethyl sulfoxide) as a reducing agent in the CaCl2 precipitation method to improve efficiency, the electroporation method, the calcium phosphate precipitation method, the protoplast fusion method, the stirring method using silicon carbide fibers, the transformation method mediated by Agrobacterium, the transformation method using PEG, dextran sulfate, lipofectamine, and the transformation method mediated by drying / inhibition, etc.
[0154] Methods for producing anti-FcRn antibody variants or antigen-binding fragments thereof
[0155] In another aspect of the present invention, a method for producing an anti-FcRn antibody or an antigen-binding fragment thereof is provided, the method comprising culturing the host cell to produce the antibody; and separating and purifying the produced antibody to recover the antibody that specifically binds to FcRn.
[0156] According to the FcRn-specific antibody of the present invention, the transformant expressing the recombinant vector can be cultured in a nutrient medium for mass production, and the tolerant culture medium and culture conditions can be appropriately selected and used according to the host cell. The conditions in the culture, such as temperature, pH value of the culture medium and culture time can be appropriately adjusted to suit cell growth and mass production of protein. The antibody or antibody fragment produced according to the above recombinant can be recovered from the culture medium or lysate and can be separated and purified by conventional biochemical separation techniques (Sambrook et al., Molecular Cloning: A laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press (1989); Deuscher, M., Guide to Protein Purification Methods Enzymology, Vol. 182. Academic Press. Inc., San Diego, CA (1990)). As examples, electrophoresis, centrifugation, gel filtration, precipitation, dialysis, chromatography (ion exchange chromatography, affinity chromatography, immunoadsorption chromatography, size exclusion chromatography, etc.), isoelectric focusing, and methods with various modifications and combinations thereof can be used, but are not limited thereto. In particular, protein A is preferably used for separation and purification.
[0157] The anti-FcRn antibody or antigen-binding fragment thereof is particularly preferably prepared by expression and purification using a genetic recombination method. Specifically, it is preferred to prepare the variable regions encoding the antibody that specifically binds to FcRn according to the present invention by simultaneously expressing them in one host cell.
[0158] Use of anti-FcRn antibody variants or antigen-binding fragments thereof
[0159] In another aspect of the present invention, a pharmaceutical composition for treating an autoimmune disease is provided, the pharmaceutical composition comprising an anti-FcRn antibody or an antigen-binding fragment thereof. Also provided herein is a method for treating an autoimmune disease, the method comprising administering an effective amount of an anti-FcRn antibody or an antigen-binding fragment thereof, or a pharmaceutical composition described herein to an individual in need thereof.
[0160] The "anti-FcRn antibody" and "antigen-binding fragment" are as described above.
[0161] As used herein, the term "autoimmune disease" is a general term for diseases that occur when the immune system attacks normal tissues, organs, or other body components due to an unexplained abnormality of the immune system. This is a systemic disease that can occur in almost any part of the body, including the nervous system, gastrointestinal system, endocrine system, skin, skeletal system, vascular tissue, etc.
[0162] The pharmaceutical composition can be applied to all autoimmune diseases mediated by IgG and FcRn. Representative autoimmune diseases may be an autoimmune disease selected from the group consisting of autoimmune neutropenia, Guillain-Barré syndrome, epilepsy, autoimmune encephalitis, Isaacs' syndrome, nevus syndrome, pemphigus vulgaris, deciduous pemphigus, bullous pemphigoid, acquired epidermolysis bullosa, gestational pemphigoid, mucous membrane pemphigoid, antiphospholipid syndrome, autoimmune anemia, autoimmune Graves' disease, Goodpasture syndrome, myasthenia gravis. gravis), multiple sclerosis, rheumatoid arthritis, lupus, idiopathic thrombocytopenic purpura (ITP), lupus nephritis, membranous nephropathy, allogeneic islet transplant rejection, alopecia areata, ankylosing spondylitis, autoimmune Addison's disease, Alzheimer's disease, antineutrophil cytoplasmic autoantibodies (ANCA), autoimmune adrenal disease, warm autoimmune hemolytic anemia (WAIHA), autoimmune hepatitis, autoimmune myocarditis, autoimmune oophoritis and orchitis, autoimmune thrombocytopenia, autoimmune urticaria urticaria), Behcet'sdisease, cardiomyopathy, Castleman's syndrome, celiac sprue-dermatitis, chronic fatigue immune dysfunction syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), Churg-Strauss syndrome, cicatrical pemphigoid, CREST syndrome, cold agglutinin disease, Crohn's disease, dermatomyositis, dilated cardiomyopathy, discoid lupus, essential mixed cryoglobulinemia cryoglobulinemia, factor VIII deficiency, fibromyalgia-fibromyositis, glomerulonephritis, thyroid eye disease (TED, also known as Graves' ophthalmopathy), graft-versus-host disease (GVHD), Hashimoto's thyroiditis, hemophilia A, idiopathic membranous neuropathy, idiopathic pulmonary fibrosis, IgA neuropathy, IgM polyneuropathy, immune mediated thrombocytopenia, juvenile arthritis, Kawasaki's disease, lichen planus, lichen sclerosus, lupus erythematosus, Meniere's disease, mixed connective tissue disease, type 1 diabetes, multifocal motor neuropathy neuropathy (MMN), paraneoplastic bullous pemphigoid, pemphigus foliaceus, pernicious anemia, polyarteritis nodosanodosa, polychrondritis, polyglandular syndromes, polymyalgia rheumatica, polymyositis and dermatomyositis, primary agammaglobinulinemia, primary biliary cirrhosis, psoriasis, psoriatic arthritis, relapsing polychondritis, Reynauld's phenomenon, Reiter's syndrome, sarcoidosis, scleroderma, Sjogren's syndrome, solid organ transplant rejection, stiff-man syndrome, systemic lupus erythematosus, takayasu arteritis, toxic epidermal necrolysis (TEN), Stevens Johnson syndrome, syndrome (SJS), temporal arteritis, giant cell arteritis, thrombotic thrombocytopenia purpura, ulcerative colitis, uveitis, dermatitis herpetiformis vasculitis, anti-neutrophil cytoplasmic antibody-associated vasculitides, vitiligo, and Wegner's granulomatosis. In some embodiments, the autoimmune disease is an autoimmune ion channel disease, wherein the ion channel disease is optionally selected from the group consisting of: autoimmune limbic encephalitis, neuromyelitis optica, Lambert-Eaton myasthenic syndrome, myasthenia gravis,gravis), anti-N-methyl-D-aspartate (NMDA) receptor encephalitis, anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis, Morvan syndrome, neuromyotonia, childhood autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS), anti-glycine receptor antibody-related diseases, myositis, myelin oligodendrocyte glycoprotein antibody disorder (MOG antibody disorder), hemolytic disease of the fetus and the newborn, cutaneous lupus erythematosus, refractory rheumatoid arthritis, immune thrombocytopenia, anti-GBM disease, primary membranous nephropathy, necrotizing autoimmune myopathy, antisynthetase syndrome, ANCA vasculitis, hidradenitis suppurativa, pulmonary alveolar proteinosis alveolar proteinosis) (PAP) and systemic lupus erythematosus (SLE), but are not limited thereto.
[0163] In some embodiments, the disease treated according to the methods described herein is characterized by an increase in the total blood IgG level of the individual to be treated or a disease showing an increase in the total blood IgG level. In some embodiments, the disease treated according to the methods described herein is any autoimmune disease mentioned herein. In some embodiments, the disease is autoimmune Graves' disease. In some embodiments, the disease is thyroid eye disease (TED, also known as Graves' eye disease). In some embodiments, the disease is warm antibody autoimmune hemolytic anemia (WAIHA). In some embodiments, the disease is myasthenia gravis. In some embodiments, the disease is chronic inflammatory demyelinating polyneuropathy (CIDP). In some embodiments, the disease is pemphigus vulgaris, pemphigus foliaceus, exfoliative pemphigus, bullous pemphigoid, pemphigoid gestationis, or mucous membrane pemphigoid.
[0164] In some embodiments, the disease treated according to the methods described herein is a disease that responds to plasma exchange therapy. The individual treated according to the methods described herein may have previously received plasma exchange. In some embodiments, the disease treated according to the methods described herein is a disease that responds to the therapy that reduces total IgG levels. The individual treated according to the methods described herein may have previously received the therapy that reduces total IgG levels. In some embodiments, the disease treated according to the methods described herein is a disease that responds to rituximab. The individual treated according to the methods described herein may have previously received rituximab treatment.
[0165] In some embodiments, the anti-FcRn antibodies or antigen-specific fragments thereof described herein reduce the level of antigen-specific immunoglobulins or autoantibodies (such as any autoantibodies described herein or known in the art). In some embodiments, the anti-FcRn antibodies or antigen-specific fragments thereof described herein reduce the level of autoantibodies specific for autoimmune diseases or reduce the level of autoantibodies associated with or known to be associated with autoimmune diseases (such as any autoantibodies described herein or known in the art). In some embodiments, the autoimmune disease is any autoimmune disease disclosed herein.
[0166] In some embodiments, administering (e.g., subcutaneously) an effective amount of an anti-FcRn antibody described herein to an individual (e.g., a human) can reduce the level of an antigen-specific immunoglobulin or autoantibody in the blood (e.g., the level of any one or more autoantibodies described herein) by at least about 40%, 50%, 65%, or 80%. In some embodiments, these administrations have no or minimal effect on blood albumin levels (e.g., reduce blood albumin by less than 10%, less than 5%, less than 2%, or less than 1%) and / or have no or minimal effect on blood LDL levels (e.g., increase LDL by less than 10%, less than 5%, less than 2%, or less than 1%) compared to the level before administration. In some embodiments, the antigen-specific immunoglobulin or autoantibody is associated with a disease such as an autoimmune disease.
[0167] In some embodiments, chronic subcutaneous administration of an effective amount of an anti-FcRn antibody described herein to a human for 12 weeks or more can reduce the level of antigen-specific immunoglobulin or autoantibody in the blood (e.g., the level of any one or more autoantibodies described herein) by at least about 40%, 50%, 65%, or 80%, compared to the level before administration, but has no effect or minimal effect on blood albumin levels (e.g., reduces blood albumin by less than 10%, less than 5%, less than 2%, or less than 1%) and has no effect or minimal effect on blood LDL and / or cholesterol levels (e.g., increases LDL and / or cholesterol by less than 10%, less than 5%, less than 2%, or less than 1%). In some embodiments, the antigen-specific immunoglobulin or autoantibody is associated with a disease such as an autoimmune disease.
[0168] Illustrative examples of autoantibodies associated with specific autoimmune diseases include:
[0169] Anti-desmoglein 3 (anti-Dsg3) antibodies (associated with pemphigus vulgaris),
[0170] Anti-desmoglein 1 (anti-Dsg1) antibodies (associated with pemphigus vulgaris and pemphigus foliaceus),
[0171] Anti-bullous pemphigoid 180 (anti-BP180 or anti-collagen XVII) antibodies and anti-bullous pemphigoid 230
[0172] (anti-BP230) antibodies (both associated with bullous pemphigoid),
[0173] Antibodies against the non-collagenous domain 1 of the 3rd chain of type IV collagen (anti-α3NC1 antibodies) and antibodies against the non-collagenous domain 1 of the 5th chain of type IV collagen (anti-α5NC1 antibodies) (both associated with anti-GBM disease),
[0174] Antiphospholipase A2 receptor (anti-PLA2R) antibodies (associated with idiopathic membranous nephropathy),
[0175] Antiproteinase 3 (anti-PR3) antibodies and anti-myeloperoxidase (anti-MPO) antibodies (both associated with ANCA-associated vasculitis),
[0176] Anti-double-stranded (ds)-DNA antibodies, antibodies to Sjögren's syndrome-associated antigen A (anti-SSA / Ro antibodies) and antibodies to Sjögren's syndrome-associated antigen B (anti-SSB / La antibodies), anti-Smith antibodies, anti-ribonucleoprotein (anti-RNP) antibodies, anti-complement C1q antibodies, anti-proliferating cell nuclear antigen (PCNA) antibodies, anti-cardiolipin antibodies, anti-β2-glycoprotein antibodies, anti-granzyme B antibodies, and anti-nucleosome antibodies (all associated with systemic lupus erythematosus),
[0177] Antinuclear antibodies (associated with systemic lupus erythematosus, systemic sclerosis, and autoimmune hepatitis),
[0178] Rheumatoid factor, anti-citrullinated peptide antibodies (ACPA), anti-CarP antibodies, and anti-acetylated peptide antibodies (AAPA) (all associated with rheumatoid arthritis),
[0179] Anticentromere antibodies (ACA), anti-Scl-70 antibodies, anti-endothelial cell antibodies (AECA), angiotensin II type 1 receptor (anti-AT1R) antibodies, and anti-endothelin type 1A receptor (anti-ETAR) antibodies (all associated with systemic sclerosis),
[0180] Anti-signal recognition particle (anti-SRP) antibodies (associated with immune-mediated necrotizing myopathy and polymyositis), Anti-HMG-CoA reductase (anti-HMGCR) antibodies (associated with immune-mediated necrotizing myopathy),
[0181] Anti-Jo-1 antibodies, anti-PL-7 antibodies, anti-PL-12 antibodies, anti-EJ antibodies, anti-OJ antibodies, anti-Mi-2 antibodies, anti-U3 ribonucleoprotein (anti-U3 RNP or anti-fibrillarin) antibodies, anti-U2 ribonucleoprotein and (anti-U2 RNP) antibodies (all associated with polymyositis),
[0182] Anti-Ku antibodies (associated with systemic lupus erythematosus and polymyositis),
[0183] Anti-nuclear matrix protein 2 (anti-NXP-2) antibodies, anti-Mi2 antibodies, anti-melanoma differentiation-associated protein 5 (anti-MDA5) antibodies, and anti-transcription intermediary factor 1-γ (anti-TIF1γ) antibodies (all associated with dermatomyositis),
[0184] Anti-acetylcholine receptor (anti-AChR) antibodies, anti-muscle-specific kinase (anti-MuSK) antibodies, and anti-lipid-related protein 4 (anti-LRP4) antibodies (all implicated in myasthenia gravis),
[0185] Anti-neurofascin-155 (anti-Nfasc155) antibodies, anti-neurofascin-140 / 186 (anti-Nfasc140 / 186) antibodies, anti-contactin-1 (anti-CNTN1) antibodies, and anti-contactin-associated protein-like 1 (anti-Caspr1) antibodies (all associated with chronic inflammatory demyelinating polyneuropathy (CIDP)),
[0186] Anti-ganglioside GM1 (anti-GM1) antibodies, anti-ganglioside GT1a (anti-GT1a) antibodies, and anti-ganglioside GD1a (anti-GD1a) antibodies (all associated with Guillain-Barré syndrome),
[0187] Anti-ganglioside GQ1b (anti-GQ1b) antibodies (associated with Guillain-Barré syndrome and Miller Fisher syndrome),
[0188] Anti-aquaporin 4 (anti-AQP4) antibodies (associated with neuromyelitis optica spectrum disorder),
[0189] Anti-NMDAR antibodies (associated with systemic lupus erythematosus and autoantibody-positive autoimmune encephalitis),
[0190] Anti-contamin-associated protein-like 2 (anti-Caspr2) antibodies, anti-gamma-aminobutyric acid type B receptor (anti-GABAbR)
[0191] Antibodies, anti-leucine-rich glioma inactivated protein 1 (anti-LGI1) antibodies and anti-Kelch-like protein 11 (anti-Klh11) antibodies
[0192] Antibodies (all associated with autoantibody-positive autoimmune encephalitis),
[0193] Anti-β2-glycoprotein I (anti-β2GPI) antibodies and antiphospholipid antibodies (both associated with primary antiphospholipid syndrome),
[0194] Anti-FcγRIIIb antibodies and anti-CD177 antibodies (both associated with primary autoimmune neutropenia),
[0195] Anti-smooth muscle actin (anti-SMA) antibodies and anti-liver and kidney microsome (anti-LKM) antibodies (both associated with autoimmune hepatitis),
[0196] Anti-ADAMTS13 antibodies (associated with idiopathic thrombotic thrombocytopenic purpura),
[0197] Antiplatelet GP IIb / IIIa antibodies and antiplatelet GP Ib / IX antibodies (both associated with idiopathic immune thrombocytopenic purpura),
[0198] Thyroid stimulating hormone (TSH) binding inhibitory immunoglobulin (TBII), thyroid stimulating immunoglobulin (TSI), thyrotropin binding inhibitory (TBI) antibodies, and anti-insulin-like growth factor 1 receptor (anti-IFG1R) antibodies (all associated with Graves’ disease and thyroid eye disease),
[0199] Anti-thyroid peroxidase (anti-TPO) antibodies (associated with autoimmune thyroiditis / Hashimoto's thyroiditis),
[0200] Antithyroglobulin antibodies (associated with Graves' disease),
[0201] Islet cell cytoplasmic autoantibodies (ICA), glutamic acid decarboxylase autoantibodies (GADA), insulinoma-associated 2 autoantibodies (IA-2A), and insulin autoantibodies (IAA) (all associated with type 1 diabetes),
[0202] Neutralizing anti-adenoviral antibodies, neutralizing anti-lentiviral antibodies, neutralizing anti-AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, and / or AAV9 antibodies (as relevant to prior gene therapy), and
[0203] Anti-granulocyte-macrophage colony-stimulating factor (anti-GM-CSF) antibodies (associated with acquired alveolar proteinosis (PAP)).
[0204] In some embodiments, administration of an effective amount of an anti-FcRn antibody described herein to a human subject (e.g., subcutaneously or chronically subcutaneously to a human) reduces proteinuria in a subject with lupus nephritis by at least about 40%, 50%, 65%, or 80%, as measured by protein levels in the subject's urine.
[0205] The preferred dosage of the pharmaceutical composition may vary according to the patient's condition and body weight, severity of the disease, drug form, route of administration and duration, but may be appropriately selected by a person skilled in the art. In the pharmaceutical composition for treating or preventing autoimmune diseases of the present invention, the active ingredient may be included in the pharmaceutical composition in any amount (effective amount) according to the purpose of use, formulation, combination, etc., as long as it can show therapeutic activity for autoimmune diseases, or especially the therapeutic effect on autoimmune diseases. A typical effective amount will be determined within the range of 0.001 wt % to 20.0 wt % based on the gross weight of the composition. As used herein, the term "effective amount" refers to the amount of active ingredients having the effect of treating or improving the state of autoimmune diseases, especially the amount of active ingredients that can induce treatment or improve the state of autoimmune diseases. These effective amounts can be determined empirically by a person of ordinary skill in the art.
[0206] In one embodiment, the term "treatment" includes any form of administration or application for treating a disease in a mammal (including a human). In addition, the above terms include inhibiting or slowing down a disease or its progression; restoring or repairing an impaired or missing function, thereby partially or completely alleviating the disease; stimulating an inefficient process; or alleviating a serious disease.
[0207] In another aspect, provided herein is a method for preventing an autoimmune disease, the method comprising administering to an individual in need thereof an effective amount of an anti-FcRn antibody, or an antigen-binding fragment thereof, or a pharmaceutical composition described herein.
[0208] Any embodiment of the method for treating an autoimmune disease comprising administering an anti-FcRn antibody, an antigen-binding fragment thereof, or a pharmaceutical composition herein encompasses the use of the anti-FcRn antibody, an antigen-binding fragment thereof, or a pharmaceutical composition in the preparation of a medicament for treating an autoimmune disease. Similarly, any embodiment of the method for preventing an autoimmune disease comprising administering an anti-FcRn antibody, an antigen-binding fragment thereof, or a pharmaceutical composition herein encompasses the use of the anti-FcRn antibody, an antigen-binding fragment thereof, or a pharmaceutical composition in the preparation of a medicament for preventing an autoimmune disease.
[0209] Pharmacokinetic parameters (such as bioavailability) and implicit parameters (such as clearance) may also affect efficacy. Therefore, "improved efficacy" (e.g., improved efficacy) can be attributed to improved pharmacokinetic parameters and improved efficacy, and can be measured by comparing parameters such as clearance and treatment or improvement of autoimmune diseases in experimental animals or human subjects.
[0210] As used herein, the term "therapeutically effective amount" or "pharmaceutically effective amount" refers to the amount of a compound or composition that effectively prevents or treats a target disease, and means an amount sufficient to treat the disease at a reasonable benefit / risk ratio applicable to medical treatment and without causing side effects. The level of the effective amount can be determined based on the following factors: the patient's health status, the type and severity of the disease, the activity of the drug, sensitivity to the drug, the method of administration, the time of administration, the route of administration and the rate of excretion, the duration of treatment, factors including drugs used in combination or simultaneously, and other factors well known in the medical field. In one embodiment, a therapeutically effective amount refers to the amount of a drug that is effective in treating an autoimmune disease.
[0211] In this regard, the pharmaceutical composition may further comprise a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may be any non-toxic material suitable for delivery to a patient. Distilled water, alcohol, fat, wax and inert solids may be included as carriers. In addition, the pharmaceutical composition may comprise a pharmaceutically acceptable adjuvant (buffer, dispersant).
[0212] Specifically, in addition to the active ingredient, the pharmaceutical composition can also contain a pharmaceutically acceptable carrier and can be prepared into a parenteral preparation by conventional methods known in the art according to the route of administration. Here, "pharmaceutically acceptable" means that it will not inhibit the activity of the active ingredient and does not have toxicity beyond the tolerable individual to which it is to be administered (prepared).
[0213] When the pharmaceutical composition is prepared as a parenteral preparation, it can be formulated into the form of injection, transdermal preparation, nasal inhalation and suppository together with a suitable carrier according to methods known in the art. The preparation of the pharmaceutical composition is known in the art, and specifically, reference can be made to the literature [Remington's Pharmaceutical Sciences (19th ed., 1995)], etc. This literature is considered to be a part of this patent specification.
[0214] The preferred dosage of the pharmaceutical composition will vary depending on the patient's physical condition, weight, sex and age, severity of the disease, route of administration, etc., and can be appropriately selected by a person skilled in the art.
[0215] The subject to which the pharmaceutical composition can be administered (prepared) is a mammal or a human, and it is particularly preferred that the subject is a human.
[0216] In another aspect of the present invention, a method for treating an autoimmune disease is provided, the method comprising administering an effective amount of an antibody or an antigen-binding fragment thereof that specifically binds to FcRn to a patient in need of treatment for the autoimmune disease.
[0217] In another aspect of the present invention, a method for alleviating autoimmune or alloimmune diseases is provided, the method comprising administering an anti-FcRn antibody or an antigen-binding fragment thereof to an individual in need thereof. In addition, a specific anti-FcRn therapy is also provided.
[0218] The method for alleviating autoimmune or alloimmune diseases or anti-FcRn therapy according to the present invention can be achieved by administering the pharmaceutical composition of the present invention to an individual. The pharmaceutical composition according to the present invention can be administered orally or parenterally. For example, it can be administered via routes of administration such as intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, topical administration, intranasal administration, intrapulmonary administration, and rectal administration. In some embodiments, the pharmaceutical composition disclosed herein is administered subcutaneously.
[0219] The preferred dosage of the pharmaceutical composition may vary depending on the patient's condition and weight, severity of the disease, drug form, administration route and duration, but can be appropriately selected by a person skilled in the art and may be administered single or repeated.
[0220] In various embodiments of the methods of treatment and uses disclosed herein, the antibody or antigen-binding fragment is administered to the patient in the form of a fixed dose. In various embodiments of the methods of treatment and uses disclosed herein, the antibody or antigen-binding fragment is administered to the patient in the form of a weight-based dosage, i.e., a dosage that depends on the patient's weight. In various embodiments of the methods of treatment and uses disclosed herein, the antibody or antigen-binding fragment is administered to the patient in the form of a dosage based on body surface area, i.e., a dosage that depends on the patient's body surface area (BSA). In various embodiments, the dose administered to the patient comprises a therapeutically effective amount of the antibody or antigen-binding fragment.
[0221] In some embodiments, the patient is given a dosage of about 300mg to about 500mg of the antibody or antigen-binding fragment. In some embodiments, the patient is given a dosage of about 300mg to about 500mg (e.g., once a week, once a month, or once every 2 weeks, or once every 3 weeks) via subcutaneous administration. In some embodiments, the patient is given (e.g., via subcutaneous administration) a dosage of about 300mg, about 310mg, about 320mg, about 330mg, about 340mg, about 350mg, about 360mg, about 370mg, about 380mg, about 390mg, about 400mg, about 410mg, about 420mg, about 430mg, about 440mg, about 450mg, about 460mg, about 470mg, about 480mg, about 490mg, or about 500mg (e.g., once a week, once a month, once every two weeks, or once every three weeks) of the antibody or antigen-binding fragment. In some embodiments, the patient is given (e.g., via subcutaneous administration) a dose of at least or more than about 300 mg (e.g., once a week, once a month, or once every two weeks) of the antibody or antigen-binding fragment. In some embodiments, the patient is given a dose of about 340 mg of the antibody or antigen-binding fragment. In some embodiments, the patient is given a dose of about 340 mg of the antibody or antigen-binding fragment once a week, once a month, or once every two weeks. In some embodiments, the patient is given a dose of about 340 mg of the antibody or antigen-binding fragment once a week. In some embodiments, the patient is given a dose of about 340 mg of the antibody or antigen-binding fragment in the form of a single subcutaneous injection once a week. In some embodiments, the patient is given a dose of about 340 mg of the antibody or antigen-binding fragment once a week for at least 2 weeks (e.g., 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 10 weeks, 12 weeks or longer). In some embodiments, the patient is given a dose of about 340 mg of the antibody or antigen-binding fragment once a week for at least 4 weeks. In some embodiments, the patient is administered a dose of about 340 mg of the antibody or antigen-binding fragment once a week for at least 7 weeks. The patient is administered a dose of about 340 mg of the antibody or antigen-binding fragment once a week for at least 12 weeks. In some embodiments, the administration is subcutaneous.
[0222] In some embodiments, the patient is given a dosage of about 500mg to about 700mg of the antibody or antigen-binding fragment. In some embodiments, the patient is given a dosage of about 500mg to about 700mg of the antibody or antigen-binding fragment via subcutaneous administration, for example, once a week, once a month, or once every 2 weeks, or once every 3 weeks. In some embodiments, the patient is given (for example, via subcutaneous administration) a dosage of about 500mg, about 510mg, about 520mg, about 530mg, about 540mg, about 550mg, about 560mg, about 570mg, about 580mg, about 590mg, about 600mg, about 610mg, about 620mg, about 630mg, about 640mg, about 650mg, about 660mg, about 670mg, about 680mg, about 690mg, or about 700mg of the antibody or antigen-binding fragment (for example, once a week, once a month, once every two weeks, or once every three weeks). In some embodiments, the patient is given (e.g., via subcutaneous) a dose of up to or less than about 750 mg or 700 mg of the antibody or antigen-binding fragment (e.g., once a week, once a month, or once every two weeks). In some embodiments, the patient is given a dose of about 680 mg of the antibody or antigen-binding fragment. In some embodiments, the patient is given a dose of about 680 mg of the antibody or antigen-binding fragment once a week, once a month, or once every two weeks. In some embodiments, the patient is given a dose of about 680 mg of the antibody or antigen-binding fragment once a week. In some embodiments, the patient is given a dose of about 680 mg of the antibody or antigen-binding fragment in the form of a continuous subcutaneous injection once a week or more (e.g., twice). In some embodiments, the patient is given a dose of about 680 mg of the antibody or antigen-binding fragment once a week for at least 2 weeks (e.g., 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 10 weeks, 12 weeks or longer). In some embodiments, the patient is administered a dose of about 680 mg of the antibody or antigen-binding fragment once a week for at least 4 weeks. In some embodiments, the patient is administered a dose of about 680 mg of the antibody or antigen-binding fragment once a week for at least 7 weeks. In some embodiments, the patient is administered a dose of about 680 mg of the antibody or antigen-binding fragment once a week for at least 12 weeks. In some embodiments, the administration is subcutaneous.
[0223] In some embodiments, the patient is administered a dose of about 100 mg, about 150 mg, about 200 mg, about 300 mg, about 400 mg, about 450 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1000 mg, about 1100 mg, about 1,200 mg, about 1300 mg, about 1400 mg, about 1500 mg, about 1600 mg, about 1700 mg, about 1800 mg, about 1900 mg, about 2000 mg, about 2100 mg, about 2200 mg, about 2300 mg, about 2400 mg, or about 2500 mg of the antibody or antigen-binding fragment. In some embodiments, the patient is administered the antibody or antigen-binding fragment via an intravenous route at a dose of about 100 mg, about 150 mg, about 200 mg, about 300 mg, about 400 mg, about 450 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1000 mg, about 1100 mg, about 1,200 mg, about 1300 mg, about 1400 mg, about 1500 mg, about 1600 mg, about 1700 mg, about 1800 mg, about 1900 mg, about 2000 mg, about 2100 mg, about 2200 mg, about 2300 mg, about 2400 mg, or about 2500 mg. In some embodiments, the patient is administered the antibody or antigen-binding fragment via a subcutaneous route at a dose of about 100 mg, about 150 mg, about 200 mg, about 300 mg, about 400 mg, about 450 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1000 mg, about 1100 mg, about 1,200 mg, about 1300 mg, about 1400 mg, about 1500 mg, about 1600 mg, about 1700 mg, about 1800 mg, about 1900 mg, about 2000 mg, about 2100 mg, about 2200 mg, about 2300 mg, about 2400 mg, or about 2500 mg.
[0224] In some embodiments, the patient is administered the antibody or antigen-binding fragment at a dosage range between any dosage values mentioned herein. In some embodiments, the patient is administered the antibody or antigen-binding fragment at a dosage less than any dosage value mentioned herein.
[0225] In some embodiments, the patient is administered a dose of about 100 mg, about 150 mg, about 200 mg, about 300 mg, about 400 mg, about 450 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1000 mg, about 1100 mg, about 1,200 mg, about 1300 mg, about 1400 mg, about 1500 mg, about 1600 mg, about 1700 mg, about 1800 mg, about 1900 mg, about 2000 mg, about 2100 mg, about 2200 mg, about 2300 mg, about 2400 mg, or about 2500 mg of the antibody or antigen-binding fragment once a week (e.g., subcutaneously).
[0226] In some embodiments, the patient is administered a dose of about 100 mg, about 150 mg, about 200 mg, about 300 mg, about 400 mg, about 450 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1000 mg, about 1100 mg, about 1,200 mg, about 1300 mg, about 1400 mg, about 1500 mg, about 1600 mg, about 1700 mg, about 1800 mg, about 1900 mg, about 2000 mg, about 2100 mg, about 2200 mg, about 2300 mg, about 2400 mg, or about 2500 mg of the antibody or antigen-binding fragment once every two weeks (e.g., subcutaneously).
[0227] In some embodiments, the patient is administered (e.g., subcutaneously) a dose of about 100 mg, about 150 mg, about 200 mg, about 300 mg, about 400 mg, about 450 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1000 mg, about 1100 mg, about 1,200 mg, about 1300 mg, about 1400 mg, about 1500 mg, about 1600 mg, about 1700 mg, about 1800 mg, about 1900 mg, about 2000 mg, about 2100 mg, about 2200 mg, about 2300 mg, about 2400 mg, or about 2500 mg of the antibody or antigen-binding fragment once every three weeks.
[0228] In some embodiments, the patient is administered a dose of about 100 mg, about 150 mg, about 200 mg, about 300 mg, about 400 mg, about 450 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, about 1000 mg, about 1100 mg, about 1,200 mg, about 1300 mg, about 1400 mg, about 1500 mg, about 1600 mg, about 1700 mg, about 1800 mg, about 1900 mg, about 2000 mg, about 2100 mg, about 2200 mg, about 2300 mg, about 2400 mg, or about 2500 mg of the antibody or antigen-binding fragment once a month (e.g., subcutaneously).
[0229] In some embodiments, the patient is administered a dose of about 300 mg, about 600 mg, about 900 mg, about 1200 mg, about 1500 mg, about 1800 mg, about 2100 mg, or about 2400 mg of the antibody or antigen-binding fragment. In some embodiments, the patient is administered an intravenous route at a dose of about 300 mg, about 600 mg, about 900 mg, about 1200 mg, about 1500 mg, about 1800 mg, about 2100 mg, or about 2400 mg of the antibody or antigen-binding fragment. In some embodiments, the patient is administered an subcutaneous route at a dose of about 300 mg, about 600 mg, about 900 mg, about 1200 mg, about 1500 mg, about 1800 mg, about 2100 mg, or about 2400 mg of the antibody or antigen-binding fragment. In some embodiments, once a week (e.g., via subcutaneous administration), the patient is given a dosage of about 300 mg, about 600 mg, about 900 mg, about 1200 mg, about 1500 mg, about 1800 mg, or about 2100 mg of the antibody or antigen-binding fragment. In some embodiments, once every two weeks (e.g., via subcutaneous administration), the patient is given a dosage of about 300 mg, about 600 mg, about 900 mg, about 1200 mg, about 1500 mg, about 1800 mg, about 2100 mg, or about 2400 mg of the antibody or antigen-binding fragment. In some embodiments, once every three weeks (e.g., via subcutaneous administration), the patient is given a dosage of about 300 mg, about 600 mg, about 900 mg, about 1200 mg, about 1500 mg, about 1800 mg, about 2100 mg, or about 2400 mg of the antibody or antigen-binding fragment. In some embodiments, the patient is administered a dose of about 300 mg, about 600 mg, about 900 mg, about 1200 mg, about 1500 mg, about 1800 mg, about 2100 mg, or about 2400 mg of the antibody or antigen-binding fragment once a month (e.g., subcutaneously).
[0230] In some embodiments, the patient is administered (e.g., subcutaneously) a dose of about 150 mg, about 300 mg, about 450 mg, about 600 mg, about 900 mg, about 1200 mg, about 1500 mg, about 1800 mg, about 2100 mg, or about 2400 mg, or any dose between any two of these doses (e.g., once a week via subcutaneous administration, once every two weeks via subcutaneous administration, once every three weeks via subcutaneous administration, or once a month via subcutaneous administration of the dose). In some embodiments, the dosages provided herein are suitable dosages for administration to humans.
[0231] In some embodiments, the antibody, Fab or pharmaceutical composition is administered to the patient once a week or once a month. In some embodiments, the antibody, Fab or pharmaceutical composition is administered to the patient once a week for at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 7 weeks, at least 8 weeks, at least 9 weeks, at least 10 weeks, at least 12 weeks, at least 20 weeks, at least 24 weeks, at least 30 weeks, at least 40 weeks, at least 50 weeks, at least 60 weeks, at least 70 weeks, at least 76 weeks, at least 80 weeks, or longer.
[0232] In some embodiments, the antibody, Fab or pharmaceutical composition is administered to the patient once every two or three weeks. In some embodiments, the antibody, Fab or pharmaceutical composition is administered to the patient once every other week (i.e., once every two weeks) for at least 2 weeks, at least 4 weeks, at least 6 weeks, at least 8 weeks, at least 10 weeks, at least 12 weeks, at least 20 weeks, at least 24 weeks, at least 30 weeks, at least 40 weeks, at least 50 weeks, at least 60 weeks, at least 70 weeks, at least 76 weeks, at least 80 weeks, or longer.
[0233] In some embodiments, the antibody, antigen binding fragment or pharmaceutical composition is administered to the patient once within three weeks for at least 3 weeks, at least 6 weeks, at least 9 weeks, at least 12 weeks, at least 18 weeks, at least 21 weeks, at least 24 weeks, at least 30 weeks, at least 42 weeks, at least 48 weeks, at least 60 weeks, at least 72 weeks, at least 78 weeks, at least 81 weeks, or longer.
[0234] In some embodiments, the antibody, antigen-binding fragment, or pharmaceutical composition is administered to the patient once a month for at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 12 months, at least 20 months, at least 24 months, at least 30 months, at least 40 months, at least 50 months, at least 60 months, at least 70 months, at least 76 months, at least 80 months, or longer.
[0235] In some embodiments, the antibody, Fab or pharmaceutical composition is administered to the patient once a week for 6 to 76 weeks or any period therebetween. In some embodiments, the antibody, Fab or pharmaceutical composition is administered to the patient once a week for at least 2 weeks, at least 3 weeks, at least 4 weeks, or at least 6 weeks. In some embodiments, the antibody, Fab or pharmaceutical composition is administered to the patient once a week for at least 4 weeks. In some embodiments, the antibody, Fab or pharmaceutical composition is administered to the patient once a week for at least 7 weeks. In some embodiments, the antibody, Fab or pharmaceutical composition is administered to the patient once a week for at least 12 weeks. In some embodiments, the antibody, Fab or pharmaceutical composition is administered to the patient once a week for at least 24 weeks. In some embodiments, the antibody, Fab or pharmaceutical composition is administered to the patient once a week for at least 52 weeks.
[0236] In some embodiments, the patient is given one or more doses (e.g., two or more different doses) of the antibody or antigen-binding fragment. For example, in some embodiments, the patient is given two different doses (e.g., at least one higher dose followed by at least one lower dose) of the antibody or antigen-binding fragment. The higher dose (e.g., the higher dose of the two different doses) may be referred to herein as an "induction" dose, i.e., a dose that can reduce the level of at least one autoantibody and / or pathogenic antibody (e.g., at least one IgG) in the patient and / or from the patient's sample. The lower dose (e.g., the lower dose of the two different doses) may be referred to herein as a "maintenance" dose, i.e., a dose that can maintain a reduced level of at least one autoantibody and / or pathogenic antibody (e.g., at least one IgG) in the patient and / or from the patient's sample after an induction dose of at least one antibody or antigen-binding fragment (e.g., about 20%-80% of the value before treatment (pre-induction dose)). In some embodiments, the maintenance dose maintains the level of at least one autoantibody and / or pathogenic antibody (e.g., at least one IgG) in the patient and / or in a sample from the patient at about or below 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75% or about 80% of the pre-treatment (pre-induction dose) value.
[0237] In some embodiments, the induction dose and the maintenance dose are alternating, for example, the patient may receive an induction dose during a first period, followed by a maintenance dose during a first period, followed by an induction dose during a second period, and optionally followed by a maintenance dose during a second period. In some embodiments, the cycle of induction and maintenance doses (giving an induction dose for a period of time, followed by a maintenance dose for a period of time is a cycle) is repeated once, twice, three times, four times, five times, six times, seven times, or ten times. In some embodiments, the cycle of induction and maintenance doses is repeated for about 3 months, about 6 months, about 12 months, about 15 months, about 18 months, about 24 months, or longer.
[0238] In some embodiments, the at least one higher dose and / or induction dose is about 680 mg or more per dose (e.g., about 680 mg per dose, about 700 mg per dose, about 720 mg per dose, about 750 mg or more per dose). In some embodiments, the at least one higher dose and / or induction dose is about 1 dose, about 2 doses, about 3 doses, about 4 doses, or about 5 doses, each dose of about 680 mg or more (e.g., about 680 mg per dose, about 700 mg per dose, about 720 mg per dose, about 750 mg or more per dose). In some embodiments, the at least one higher dose and / or induction dose is about 3 doses, each dose of about 680 mg or more (e.g., about 680 mg per dose, about 700 mg per dose, about 720 mg per dose, about 750 mg or more per dose).
[0239] In some embodiments, at least one higher dose and / or induction dose is administered to a patient once a week, once every two weeks, or once a month. In some embodiments, at least one higher dose and / or induction dose is administered to a patient via an intravenous route. In some embodiments, at least one higher dose and / or induction dose is administered to a patient via a subcutaneous route. In some embodiments, each higher dose is administered to a patient in the form of one or more subcutaneous injections. In some embodiments, each higher dose is administered to a patient in the form of two consecutive subcutaneous injections.
[0240] In some embodiments, the at least one lower dose and / or maintenance dose is about 340 mg or more per dose (for example, each dose is about 340 mg, about 360 mg, about 380 mg, about 400 mg or more). In some embodiments, the at least one lower dose and / or maintenance dose is about 1 dose, about 2 doses, about 3 doses, about 4 doses, or about 5 doses, and each dose is about 340 mg or more (for example, each dose is about 340 mg, about 360 mg, about 380 mg, about 400 mg or more). In some embodiments, the at least one lower dose and / or maintenance dose is about 3 doses, and each dose is about 340 mg or more (for example, each dose is about 340 mg, about 360 mg, about 380 mg, about 400 mg or more). In some embodiments, at least one lower dose and / or maintenance dose is given to the patient once a week, once every two weeks, or once a month. In some embodiments, the at least one lower dose and / or maintenance dose is given to the patient via subcutaneous administration. In some embodiments, each lower dose is administered to the patient as one or more subcutaneous injections. In some embodiments, each lower dose is administered to the patient as one subcutaneous injection.
[0241] Hereinafter, the present invention will be described in more detail by the following examples. However, the following examples are only for illustrating the present invention, and the scope of the present invention is not limited thereto.
[0242] I. Designing variants to improve the physical properties of the HL161AN antibody
[0243] To improve the stability of HL161AN through molecular engineering, Lonza computer simulation tools and LC-MS / MS analysis were used to identify amino acid positions that may affect stability and design variants. The schematic diagram of the computer simulation design of HL161AN variants is shown in Figure 1 middle.
[0244] Therapeutic proteins, including antibodies, exist in heterogeneous forms due to post-translational modifications (PTMs) and chemical modifications. Modifications include glycosylation, deamidation, oxidation, etc., and the occurrence of modifications is known to depend on the host cell system, manufacturing process, storage conditions, etc. This modification is considered a major challenge in the production of therapeutic proteins because it can lead to side effects such as reduced efficacy, limited shelf life, and immune responses due to aggregation (De Groot 2006).
[0245] HL161AN is a modified human IgG1 anti-hFcRn antibody with high affinity for human FcRn (2×10 -10M) and had a high PD effect in in vivo studies in cynomolgus monkeys. However, its disadvantages are low thermal stability (about 58.4°C), aggregation at concentrations of 30 mg / mL or higher, and many charge variants identified in CEX-HPLC and cIEF analysis. Therefore, we used computer simulation tools to find PTM sites and major aggregation sites based on the amino acid sequence and X-ray crystal structure analysis results, and we identified the modified sites through LC-MS / MS analysis of this HL161AN sample. Then, by combining these two results, we tried to design variants that could potentially reduce the risk of PTMs and aggregation.
[0246] Example 1. In silico assessment of aggregation risk and PTM risk
[0247] The risk of aggregation and post-translational modifications were predicted by in silico analysis.
[0248] Protein aggregation is affected by environmental factors (such as pH, concentration, buffer, excipients, shear force, etc.) as well as intrinsic properties. To predict the risk of aggregation based on amino acid sequence, Lonza's Sentinel APART TM This is a validated program based on experimental results of over 500 antibodies for aggregation. The risk of aggregation is predicted when the sequence of the test antibody is entered. The Sentinel APART algorithm predicts that HL161AN will have an increased risk of aggregation.
[0249] In addition, using an in silico tool developed by Lonza, the following post-translational modifications (PTMs) were predicted ( Figure 2 and Figure 3 ). Specifically, the risks of post-translational modifications should be considered as follows: i) asparagine deamidation, ii) aspartate isomerization and fragmentation, iii) C-terminal lysine cleavage, iv) Fc ADCC / CDC reaction, half-life and protein A purification, v) free cysteine thiol groups, vi) N-glycosylation, O-glycosylation, vii) oxidation, and viii) pyroglutamate formation, etc.
[0250] The results of the HL161AN amino acid sequence analysis predicted the possibility of asparagine deamidation at 4 sites in the light chain (L) and 12 sites in the heavy chain (H). Most of these sites are conservative asparagine, and the risk is expected to be low. In addition, 4 sites have the possibility of deamidation, but they do not correspond to the CDR region, so it is confirmed that protein engineering is not required. Therefore, the analysis result shows that only L:Asn25 in the light chain CDR region requires protein engineering.
[0251] Furthermore, free cysteine thiol groups lead to protein misfolding, aggregation, nonspecific tissue binding, immunogenicity, and potentially low productivity. Confirmation of whether HL161AN possesses free cysteine thiol groups led to the discovery of a free thiol group in H:Cys32 and the determination that protein engineering of this amino acid was necessary.
[0252] Example 2. Analysis of PTM sites by LC-MS / MS analysis
[0253] Deamidation and oxidation modifications of two batches of HL161AN were analyzed by LC-MS / MS. 100% sequence coverage was confirmed based on peptide matching results using two enzymes, namely trypsin + Lys C mixture and chymotrypsin ( Figure 4 ).
[0254] According to the results of modification analysis, deamidation and oxidation were confirmed to occur at 7 and 6 sites, respectively, in the HL161AN internal standard sample, and deamidation and oxidation were confirmed to occur at 10 and 8 sites, respectively, in the HL161AN B012 sample.
[0255] The deamidation and oxidation sites of the HL161AN sample obtained by LC-MS / MS analysis are summarized and shown in Tables 2 and 3 below, respectively.
[0256] [Table 2]
[0257] Location Internal Standard HL161AN B012 L:Asn25 √ L:Gln36 √ L:Gln37 √ L:Asn130 √ H:Asn74 √ H:Gln82 √ H:Asn84 √ H:Gln113 √ √ H:Asn280 √ H:Asn319 √ √ H:Gln351 √ H:Asn388 √ √ H:Gln390 √ H:Gln422 √ Total 7 10
[0258] [Table 3]
[0259] Location Internal Standard HL161AN B012 L:Trp34 √ √ L:Trp197 √ H:Met34 √ √ H:Met83 √ √ H:Trp102 √ H:Met256 √ √ H:Asn319 √ √ H:Asn388 √ √ Total 6 8
[0260] Example 3. Selection of sites to be engineered
[0261] Based on the computer simulation analysis results and LC-MS / MS results, the replacement amino acids for the three amino acid sites (L: Asn25, H: Cys32, H: Gln82) that were determined to require engineering treatment were selected. From the X-ray crystal structure analysis data, these three amino acid sites are far away from the CDR region that binds to the target antigen, so it is determined that the substitution will not affect the affinity ( Figure 5). In selecting amino acid substitutions, it was determined that replacing L:Asn25 with serine (Ser) or glutamine (Gln); replacing H:Cys32 with serine (Ser) or tyrosine (Tyr); and replacing H:Gln82 with serine (Ser), threonine (Thr) or glutamic acid (Glu) can reduce the risk of PTM. In each amino acid selection method, chemically similar side chain substitution methods are used, such as replacing asparagine with glutamine (Table 4). Based on these results, 2 light chains and 11 heavy chains were designed (Table 5).
[0262] The suggested substitutions for the selected PTM sites are summarized and shown in Table 4 below, while the designed HL161AN variants are summarized and shown in Table 5 below.
[0263] [Table 4]
[0264]
[0265] [Table 5]
[0266]
[0267]
[0268] The above series of results are combined as follows.
[0269] To improve the stability of HL161AN by molecular engineering, Lonza in silico tools and LC-MS / MS analysis were used to identify amino acid positions that may affect stability and to design variants by mutagenesis.
[0270] Therefore, it was determined that three amino acid sites (L:Asn25, H:Cys32, H:Gln82) of the HL161AN antibody needed engineering treatment. It was determined that replacing L:Asn25 with serine or glutamine; replacing H:Cys32 with serine or tyrosine; and replacing H:Gln82 with serine, threonine, or glutamate could reduce the risk of PTM. A total of 22 HL161AN variants (2 light chains and 11 heavy chains of HL161AN variants) were designed by amino acid substitution.
[0271] Afterwards, 22 variants were prepared by site-directed mutagenesis, and antibodies with improved stability were screened by in vitro and in vivo evaluations.
[0272] II. In vitro screening of HL161AN antibody variants
[0273] HL161AN has excellent in vitro / in vivo pharmacological efficacy, but its disadvantages are that its physicochemical properties are poor, so the storage stability is poor, and it is difficult to prepare high concentration SC (subcutaneous). In order to improve this, the amino acid sequence and molecular structure of HL161AN were analyzed according to the above determination of sites that may affect antibody stability, and a total of 22 HL161AN variants were prepared by engineering the derived amino acid sites (Table 6). Hereinafter, the 22 HL161AN variants obtained by production were evaluated in vitro.
[0274] Preparation Example 1. Preparation method of test material
[0275] Preparation Example 1.1. HL161AN reference standard sample (reference standard, RS): Control group 1
[0276] -Batch number: HL161AN / 16E11 / ST01
[0277] -Concentration: 13mg / mL
[0278] - Preparation buffer: 100mM histidine, 100mM arginine-HCl, pH 6.0
[0279] -Storage conditions: ≤-60℃
[0280] Preparation Example 1.2. HL161AN variant plasmid
[0281] -2 light chain mutations and 11 heavy chain mutations
[0282] -Storage conditions: ≤-60℃
[0283] In the amino acid sequence of HL161AN, two or more amino acids were substituted as shown in Table 6 below.
[0284] [Table 6]
[0285]
[0286] Example 4. First in vitro evaluation of 22 HL161AN variants
[0287] The 22 HL161AN variants were evaluated in comparison to the control antibody HL161AN.
[0288] Example 4.1. Sample preparation
[0289] One day before transfection, Expi293F cells were plated at 1x10 6Cells / mL (100 mL volume) were inoculated in a 500 mL Erlenmeyer flask and then incubated in an 8% CO2 incubator at 125 rpm and 37°C for 24 hours with shaking. On the day of transfection, the cell concentration was adjusted to 2x10 6 Cells / mL were added and then the cells were transfected with plasmid DNA of each variant. Antibody plasmids were diluted to 1 μg / μL in LAL water (Lonza Bioscience). 0.12 mL of heavy chain plasmid and 0.12 mL of light chain plasmid were added to 5 mL of Opti-MEM SFM, respectively, and the plasmids were suspended. 0.24 mL of FectoPro was added to 5 mL of Opti-MEM SFM, and suspended.
[0290] Plasmid DNA and FectoPro were mixed 1:1 and incubated at room temperature for 10 minutes before being added to the flask containing the cells. The cells were incubated in an 8% CO2 incubator at 125 rpm and 37°C for 3 hours while shaking, and then 100 μL Booster was added to continue the culture. On the 6th day of culture, the culture was placed in a 250 mL centrifuge bottle and centrifuged at 3000 rpm for 15 minutes, then only the supernatant was collected and filtered through a 0.2 μm bottle top filter. The antibody expression level in the recovered culture medium was quantified using a Cedex bioanalyzer.
[0291] Therefore, all 22 HL161AN antibody variants were transiently expressed using Expi293F cells. Transfection was performed at a 100 mL culture scale to obtain 0.5 mg or more of each antibody expression medium, and the medium was harvested on day 6. The expression level in the resulting medium was 65 mg / L to 181 mg / L (Table 7). The production results of these 22 HL161AN variants are summarized and shown in Table 7 below.
[0292] [Table 7]
[0293]
[0294] Example 4.2. Purification of Antibodies
[0295] By adding 1.5mL MabSelect SuRe TM LX resin filling Chromatographic column is used for sample purification. 1X PBS (pH 7.4) is used as binding buffer and washing buffer and 1.5mL of 0.1M glycine (pH 3.0) buffer is used for elution by fractionation. All fractionation tubes are neutralized to pH 7.0 by adding 1M Tris-HCl (pH 9.0) and then collected. Buffer exchange is used to purify the collected eluent using citrate phosphate buffer (pH 8.0) and is concentrated to 1.0mg / mL using Millipore centricon (cut-off value is 30kDa). HL161AN RS is also used for in vitro evaluation, which is based on the same mode as HL161AN variant, by using citrate phosphate buffer (pH 8.0) to carry out buffer exchange. In each sample, Nanodrop is used to measure A280 value and calculate concentration. According to the quantitative value of each antibody, the state of the sample is confirmed by SDS-PAGE analysis.
[0296] Therefore, the obtained culture fluid was purified using a Protein A column and concentrated to a concentration of 1.0 mg / mL, which was obtained by transiently expressing a total of 22 HL161AN antibody variants using Expi293F cells. The purity of the resulting sample was confirmed to be 97% or higher by SDS-PAGE and SEC-HPLC analysis ( Figure 6 and Table 7).
[0297] Example 4.3. SPR analysis
[0298] SPR (surface plasmon resonance) analysis was performed using a Proteon XPR36 device at pH 6.0 and pH 7.4. shFcRn (soluble human FcRn) was immobilized on a GLC chip, and the antibody sample was reacted at 5 concentrations, and then the sensorgram results were obtained. Kinetic analysis was performed using a 1:1 Langmuir binding model, and the analysis was repeated 6 times under each condition of pH 6.0 and pH 7.4 to obtain the average KD value.
[0299] The chip was activated under EDAC / NHS 0.5X, 30 μL / min and 300 seconds. Afterwards, 250 μL of 2 μg / mL shFcRn was prepared using acetate buffer (pH 5.5) and immobilized at a flow rate of 30 μL / min. The reaction was stopped when the immobilization level was equivalent to 200RU to 300RU. Afterwards, 30 μL / min of ethanolamine was used to inactivate the activation for 300 seconds. Based on a 10 nM concentration, antibody samples of 1 / 2 nM to 5 nM, 2.5 nM, 1.25 nM, 0.625 nM and 0.312 nM were prepared by serial dilution. Depending on the analytical pH value, the sample was diluted using 1X PBST (pH 7.4) or 1X PBST (pH 6.0) buffer. Under sample analysis conditions, binding was performed at 50 μL / min for 200 seconds and dissociation was performed at 50 μL / min for 600 seconds. After that, glycine buffer (pH 2.0) was reacted at 100 μL / min for 18 seconds for regeneration. In terms of kinetic analysis, samples were prepared and reacted once in three cells on which shFcRn was immobilized. Then, three kinetic values were obtained, and then the average KD value was measured. When analyzing the reaction signal, an inter-point reference and a signal in which only the buffer was analyzed were used for double reference.
[0300] As described above, SPR analysis was performed on 22 HL161AN antibody variants at pH 6.0 and pH 7.4. The results showed that the HL161AN variants exhibited similar binding affinities (1.16E-10 M (at pH 6.0) and 2.94E-10 M (at pH 7.4)) compared to the binding affinity of HL161AN to shFcRn ( Figure 7 and Table 8).
[0301] The kinetic results for this HL161AN variant are summarized and shown in Table 8 below.
[0302] [Table 8]
[0303]
[0304]
[0305] Example 4.4. Analysis of hFcRn binding of antibody variants using FACS
[0306] hFcRn binding was analyzed using FACS at both pH 6.0 and pH 7.4. HEK293 cells expressing hFcRn (hFcRn HEK293) were diluted with reaction buffer (0.05% BSA in PBS, pH 6.0 or pH 7.4) and duplicate plates containing 1×10 5Each sample of cells. In addition, each antibody sample was diluted to 10 nM using reaction buffer, then placed in a 96-well plate and incubated at 4 ° C for 90 minutes. Afterwards, the plate was centrifuged to remove the supernatant, and then Alexa488-goat anti-hIgG Ab (1:200) was added thereto, and incubated again at 4 ° C for 90 minutes. After the reaction was completed, the plate was centrifuged to remove the supernatant, 200 μL of reaction buffer was added to resuspend the cell pellet, and then the MFI value was measured in a FACS instrument.
[0307] As described above, the binding of 22 HL161AN antibody variants was evaluated using FACS at pH 6.0 and pH 7.4. The results showed that the 22 HL161AN variants exhibited MFI values similar to that of HL161AN ( Figure 8 ).
[0308] Example 4.5. Analysis of hFcRn blocking ability of antibodies using FACS
[0309] 1×10 7 hFcRn HEK293 cells were seeded in T75 flasks and cultured for 24 h. After culture, the cells were removed and 1 × 10 5 Cells were placed in a 96-well plate in duplicate. After that, each antibody sample (0.2nM, 2nM, 20nM and 200nM) and 100nM Alexa488-hIgG1 were added in a 1:1 ratio and incubated at 4°C for 90 minutes. After the reaction was completed, it was centrifuged to remove the supernatant. 200μL of reaction buffer was added to resuspend the cell pellet, and then the MFI value was measured in a FACS instrument. Each MFI value was converted to % blocking rate, and the EC was obtained by 4-PL fitting. 50 value.
[0310] Therefore, FACS was used to assess blocking at 0.1 nM, 1 nM, 10 nM, and 100 nM. Each antibody blocked in a concentration-dependent manner, and the EC 50 Similar to the results of hFcRn binding analysis using FACS, the EC values of these 22 HL161AN variants were 50 The values were confirmed with the EC values of the control antibody HL161AN 50 Therefore, it was determined that the amino acid substitution did not affect the function of the HL161AN variant ( Fig. 9 ).
[0311] Example 4.6. Evaluation of stability
[0312] 200 μL of the purified samples were each dispensed into 1.5 mL tubes, and the samples were then stored at 40°C under accelerated conditions for up to 4 weeks, and the samples at weeks 0, 1, 2, and 4 were analyzed by SEC-HPLC. Each sample analysis was performed under the SEC-HPLC analysis conditions shown in Table 9 below, and the degree of stability under accelerated conditions was analyzed.
[0313] [Table 9]
[0314] column TSK G3000SWXL Mobile phase 0.2M potassium phosphate, 0.25M potassium chloride, pH 6.2 temperature Column 25℃, sample 4℃ UV detection 214nm Injection volume 100μL Flow rate 0.5mL / min Run time 30 minutes
[0315] The samples were stored at 40°C accelerated conditions for up to 4 weeks and the stability of the samples was analyzed by SEC-HPLC. The results showed that in the case of HL161AN, the aggregates increased by 47.5% and the fragments increased by 4.8% in the samples at week 4 compared with the samples at week 0. On the other hand, the aggregate generation rates of the 22 variants were 5.6% to 39.6%, which were decreased compared with HL161AN, while the fragment generation rates were 3.2% to 12.3%, which were increased or similar to those of HL161AN ( Fig.10 , Fig.11 and Table 10).
[0316] [Table 10]
[0317]
[0318] Example 4.7. DSC analysis
[0319] Differential scanning calorimetry (DSC) analysis was performed using a NANO DSC instrument (TA Instrument, PN: 602000, SN: K10126), and Tm values were analyzed using NanoAnalyze software using a two-phase scaling model. DSC analysis was performed by K BioHealth (Osong Medical Innovation Foundation, New Drug Development Support Center).
[0320] The thermal stability of the HL161AN variant was analyzed. The results showed that, as shown in Table 11 below, the Tm value of HL161AN was 58.4°C, while the Tm value of the HL161AN variant was 60°C to 61.5°C. Therefore, it was confirmed that the Tm value of the HL161AN variant increased by up to 2°C compared to HL161AN.
[0321] The thermal stability of the HL161AN variant is summarized and shown in Table 11 below.
[0322] [Table 11]
[0323]
[0324]
[0325] The results of the first in vitro evaluation of the above 22 HL161AN variants are summarized and shown in Table 12 below.
[0326] A total of 22 HL161AN variants were evaluated for FcRn binding affinity / blocking and stability. The results confirmed that the binding affinity and blocking effect were similar to those of HL161AN, and in terms of aggregate formation, all HL161AN variants had improved stability compared to HL161AN. Therefore, the top eight variants with an aggregate formation rate reduced to less than 10% when stored at 40°C for 4 weeks were selected, and the final lead molecule was selected after preparing high-concentration samples and performing a second in vitro screening.
[0327] [Table 12]
[0328]
[0329] 1) Transient expression level of Expi293F, >150mg / L (+++), 100mg / L to 150mg / L (++), <100mg / L (+)
[0330] 2) hFcRn is immobilized on a chip and reacted with an antibody.
[0331] 3) Analysis of the aggregation increase rate (%) at pH 8.0 and 40°C by SEC-HPLC
[0332] Example 5. Second in vitro evaluation of high concentration samples of eight HL161AN variants
[0333] These eight high concentration HL161AN variants and the control antibody HL161AN were evaluated.
[0334] Example 5.1. Sample preparation
[0335] The culture method for producing high-concentration samples was the same as that of Example 4.1. In order to obtain 120 mg or more of the antibody, 1 L or more of each antibody variant was cultured.
[0336] Example 5.2. Purification of Antibodies
[0337] The purification method of the sample is the same as that of Example 4.2, and the eluent is buffer exchanged with 50 mM histidine buffer (pH 5.0) and concentrated to a concentration of about 150 mg / mL to complete the purification. In the case of HL161AN RS, the eluent is buffer exchanged with 50 mM histidine (pH 5.0) and concentrated to a concentration of about 150 mg / mL to obtain the sample in the same manner as the HL161AN variant. In each antibody sample, the concentration was calculated using Nanodrop, and SDS-PAGE analysis was performed on this basis to confirm the sample status.
[0338] Example 5.3. Preparation of high concentration samples of HL161AN variant
[0339] In the same manner as in Examples 5.1 and 5.2 above, eight HL161AN variants selected in the first in vitro evaluation were transiently expressed in Expi293F cells and purified to prepare a concentration of 150 mg / mL or higher. HL161AN was used by concentrating the standard product to a high concentration. After the samples were produced, all samples were analyzed by A280 and SEC-HPLC (Table 13), and it was confirmed that all samples had a purity of 98% or higher except for variants No. 2 and No. 13. In the case of variants No. 2 and No. 13, precipitates were observed during the concentration process and the SEC-HPLC purity was confirmed to be as low as about 93% (Table 13).
[0340] [Table 13]
[0341]
[0342] Example 5.4. Analysis of hFcRn Binding of Antibodies Using FACS
[0343] The same method as in Example 4.4 was used. In terms of these 8 high-concentration HL161AN variants and HL161AN, hFcRn binding was evaluated using FACS at pH 6.0 and pH 7.4. The results showed that these 8 HL161AN variants showed MFI values similar to those of HL161AN (pH 6.0: 2952, pH 7.4: 7155) ( Fig.12 ).
[0344] Example 5.5. Analysis of hFcRn Blockade by Antibodies Using FACS
[0345] The same procedure as in Example 4.5 was followed. FACS was used to assess hFcRn blocking at 0.1 nM, 1 nM, 10 nM and 100 nM. Each antibody blocked in a concentration-dependent manner, and the EC 50The EC values of the control antibody HL161AN were 50 Similar values ( Fig.13 ).
[0346] Example 5.6. Evaluation of stability
[0347] The same method as in Example 4.6 was used to evaluate the stability of the eight high-concentration HL161AN variants. The changes in the purity of samples stored at 40°C for 4 weeks were measured by SDS-PAGE and SEC-HPLC. In the case of HL161AN, the generation rate of aggregates was 50% or more when stored for 4 weeks, which was also confirmed by SDS-PAGE ( Fig.14 In the case of the eight HL161AN variants, the generation rate of this aggregate was confirmed to be 8.4% to 25.7%, which was an improvement compared with HL161AN, where the generation rate of this fragment was 3.5% to 4.4%, which was similar to the generation rate of HL161AN (4.1%) ( Fig.15 ).
[0348] Example 5.7. Analysis of viscosity
[0349] The VROC chip was mounted on the body of the viscometer (m-VROC system), and then about 300 μL of the high-concentration HL161AN RS control sample and the HL161AN variant sample were each loaded into the syringe. The VROC chip was connected to the syringe, and after stabilization at the set temperature of 25°C, the viscosity was measured three times.
[0350] The viscosity of the control substance HL161AN and the four high concentration HL161AN variants with sufficient sample volume was analyzed. The viscosity of the buffer (50 mM histidine) was measured to be 0.93 cP. The average viscosity of the four HL161AN variants measured was 5.57 cP to 7.65 cP, which is lower than the viscosity that can be administered subcutaneously (sc) (<20 cP) (Table 14). The viscosity of the four high concentration HL161AN variants is summarized and shown in Table 14 below.
[0351] [Table 14]
[0352]
[0353]
[0354] The results of the second in vitro evaluation of high concentration (150 mg / mL to 170 mg / mL) samples of the above eight HL161AN variants are summarized and shown in Table 15 below.
[0355] High concentration samples of 150 mg / mL to 163 mg / mL of the eight HL161AN variants selected in the first in vitro evaluation were prepared, and FcRn binding / blocking and stability were measured to select lead molecules. The results showed that HL161AN variants 1 and 12 were selected as lead molecules, which had similar FcRn binding / blocking effects and improved stability to HL161AN (Table 15).
[0356] [Table 15]
[0357]
[0358] 1) Transient expression, >200mg / L: +++, <200mg / L: ++
[0359] 2) After storage at 40°C for 4 weeks, SEC-HPLC analysis was performed.
[0360] 3)-: Not tested.
[0361] Example 6. Conclusion of in vitro screening of HL161AN antibody variants
[0362] In order to evaluate in vitro 22 HL161AN variants designed to improve the physical properties of HL161AN, a total of 22 HL161AN variants were generated and FcRn binding affinity / blocking and stability were measured. The results showed that all 22 variants showed similar biological activity to HL161AN, and the first eight variants with improved stability were first selected. High concentration samples (150 mg / mL to 163 mg / mL) of the selected eight variants were prepared and stability was evaluated. The results showed that all eight HL161AN variants showed similar biological activity to HL161AN and had improved stability compared to HL161AN.
[0363] The light chain N25S mutation was added to HL161AN variants 1, 2, 8, and 11, and the N25Q mutation was added to HL161AN variants 12, 13, 19, and 22. However, there was no difference in stability between the two groups. In the case of the heavy chain, C32 was further mutated to S or Y, and Q82 was further mutated to S, T, or E. However, compared with the control group HL161AN, the aggregation generation rate in all variants was reduced by at least 2 times. In particular, when C32 was mutated to S, the aggregation generation rate (10% or less) was reduced to less than 1 / 5 compared with HL161AN, and the stability was improved the most compared with other variants ( Fig.16). Therefore, HL161AN variant 1 (LC: N25S, HC: C32S; HL161ANS) and variant 12 (LC: N25Q, HC: C32S; HL161ANQ) with aggregation generation rates of 10% or less were finally selected as lead molecules.
[0364] III. Evaluation of hIgG Catabolism of HL161AN Antibody Variants Using hFcRn Transgenic Mice
[0365] The in vivo hIgG catabolic efficacy of three HL161AN variants engineered for improved stability was evaluated using hFcRn transgenic (Tg) 32 mice.
[0366] The test material for the hIgG catabolism test of anti-FcRn antibody (HL161AN) variants was prepared as follows using hFcRn transgenic mice. The test material information is shown in Table 16. The three HL161AN variants HL161ANS-IgG1LALA, HL161ANQ-IgG1LALA and HL161ANQ-IgG4S228P were diluted with the buffer shown in Table 16 below to prepare 2 mg / mL. 10 mL to be administered to 5 animals was prepared, the dose was divided into 4 doses of 2.5 mL / day, and stored at ≤-60°C until administration.
[0367] [Table 16]
[0368]
[0369] In addition, HL161AN was prepared as a comparative substance as shown in Table 17. HL161AN was diluted using 50 mM histidine (pH 5.9) dilution buffer to prepare 2 mg / mL. 10 mL to be administered to 5 animals was prepared, the dose was divided into 4 doses of 2.5 mL / day, and stored at ≤-60°C until administration.
[0370] [Table 17]
[0371]
[0372] As a control substance, IV-globulin SN injection (IVIG), a product commercially available from GC Biopharma, was used. Product information is shown in Table 18. Specifically, 0.4 mL of 50 mg / mL IV-globulin injection was diluted to a concentration of 2 mg / mL by adding 9.6 mL PBS (pH 7.4) and divided into 4 doses of 2.5 mL / day and stored at 4°C for up to 4 days until administration.
[0373] [Table 18]
[0374] dose 2,500mg / 50mL(50mg / mL) Storage conditions Keep refrigerated (4℃) Manufacturer GC Biopharma
[0375] In addition, the tracer was prepared by mixing 495 mg / kg of total hIgG and 5 mg / kg of biotin-hIgG. Specifically, 0.2 mL of PBS (pH 7.4) was added to 19.8 mL of 50 mg / mL IV-globulin injection to prepare a total hIgG concentration of 49.5 mg / mL to give 495 mg / kg of IV-globulin injection. In addition, 267 μL of 10 mM biotin was added to 20 mg of IV-globulin injection to prepare biotin-hIgG, which was then incubated at room temperature for 30 minutes. Afterwards, in order to remove free biotin, the sample was transferred to a dialysis bag and dialyzed using 1X PBS (pH 7.4). By measuring UV 280 nm The biotinylated hIgG was quantified by measuring the absorbance at 280 nm (IgG E1% = 14.0).
[0376] Example 7. Animal Experiment Methods
[0377] Identify the reared mFcRn by the number on the tail - / - hFcRn transgenic (Tg) 32 mice (Jackson Laboratory, USA) (male, 5 to 10 weeks old) were placed in 5 mice per cage. After enrollment, they were acclimatized for 1 to 2 weeks. In addition, the sample substances were administered in groups as shown in Table 19 below.
[0378] [Table 19]
[0379] Group Concentration (mg / kg) Route of administration Number of animals* <![CDATA[Vehicle 1) ]]> - <![CDATA[i.p. 2) ]]> 4 HL161ANS(IgG1-LALA) 20 ip 4 HL161ANQ(IgG1-LALA) 20 ip 4 HL161ANQ(IgG4 S228P) 20 ip 4 HL161AN 20 ip 4 IVIG 20 ip 4
[0380] *Five animals per group were dosed, including one animal in each group as a spare.
[0381] 1) Carrier: 50 mM histidine, pH 5.9
[0382] 2) ip: intraperitoneal injection
[0383] Specifically, 495 mg / kg total hIgG and 5 mg / kg biotin-hIgG were administered via the intraperitoneal route (ip) at a dose of 10 mL / kg as tracers, and the administration time was set to 0 hours. In addition, after the tracer was administered, the test substances HL161ANS (IgG1-LALA), HL161ANQ (IgG1-LALA), HL161ANQ (IgG4 S228P), the comparative substance HL161AN, and the control substances vehicle and IVIG were administered 4 times via the intraperitoneal route (ip) at a dose of 20 mg / kg at 24, 48, 72, and 96 hours.
[0384] After that, the tracer administration time was set to 0 hours, and then blood was collected after 24, 48, 72, 96, 120 and 168 hours. The test substance, comparative substance and control substance were administered at 24, 48, 72 and 96 hours. In this case, blood was collected first, and then the administration was performed. The mice were anesthetized using a respiratory anesthesia device, and then blood was collected from the orbital venous plexus using a microhematocrit capillary.
[0385] About 0.2 mL of whole blood was centrifuged at 3000 rpm for 15 minutes. Afterwards, the resulting serum was transferred to a 1.5 mL microcentrifuge tube and stored at ≤ -60°C until analysis.
[0386] Example 8. Confirmation of the degree of catabolism of biotin-hIgG tracer using ELISA analysis
[0387] The serum obtained by the above method was used to confirm the extent of catabolism of the biotin-hIgG tracer in vivo.
[0388] Specifically, diluent solution / blocking buffer (Assay Diluent (AD), 1% BSA in 1X PBS, pH 7.4): 10 g Dissolve in 900mL of 1X PBS (pH 7.4), adjust to a final volume of 1L, filter through a 0.2μm filter, and then store at 4°C. In addition, 40μg / mL is obtained by mixing 10μL of biotin-hIgG (4mg / mL) with 990μL of PBS to prepare a standard stock solution (500ng / mL biotin-hIgG). Then, 750μL of this diluent is mixed with 250μL of 40μg / mL biotin-hIgG to prepare 10μg / mL. 50μL of 10μg / mL biotin-hIgG is mixed with 950μL of diluent to prepare a standard stock solution of 500ng / mL, and then aliquoted into 50μL aliquots. The aliquoted standard stock solution is stored at -80°C. In addition, neutravidin was used by diluting 10 μL of 2 mg / mL neutravidin to 2 μg / mL with 10 mL of 1X PBS.
[0389] Afterwards, all samples of the vehicle and IVIG groups were diluted 1:10,000 using dilution solution to prepare analytical samples. Except for the HL161ANS (IgG1-LALA) group, samples at 24, 48, and 72 hours were diluted 1:10,000, while samples at 96, 120, and 168 hours were diluted 1:1,000. In the case of the HL161ANS (IgG1-LALA) group, only the sample at 168 hours was diluted 1:1,000, and all samples at other time points were diluted 1:10,000. The diluted samples were loaded at 100 μL per well, in duplicate, and incubated at room temperature for 2 hours.
[0390] The blood concentration of biotin-hIgG administered at 0 hours was measured by ELISA 24, 48, 72, 96, 120 and 168 hours after administration of 20 mg / kg of HL161ANS (IgG1-LALA), HL161ANQ (IgG1-LALA), HL161ANQ (IgG4S228P), HL161AN and IVIG. The results showed that the other test groups showed a significant decrease in biotin-hIgG over time compared to the vehicle and IVIG administration groups. On the other hand, there were no significant differences between the three HL161AN variants and HL161AN. Among the three variants, HL161ANQ (LC: N25Q, HC: C32S) -IgG1-LALA showed a relatively high effect on the catabolism of biotin-hIgG. However, there was no statistical significance and was therefore determined to be similar in effect (Tables 20, 21 and Fig.17 ).
[0391] The concentrations of biotin-hlgG after administration of 20 mg / kg of the HL161AN variant are summarized and shown in Table 20 below.
[0392] [Table 20]
[0393]
[0394] The results of biotin-hlgG catabolism (% 24 hours after tracer administration) of this HL161AN variant in Tg32 mice are summarized and shown in Table 21 below.
[0395] [Table 21]
[0396]
[0397] Example 9. Calculation of the half-life of biotin-IgG tracer by pharmacokinetic (PK) analysis
[0398] The half-life of each test substance after tracer administration was calculated using the results of the biotin-hIgG ELISA quantitative analysis using the BA calculator (2007, Korea). Specifically, the half-life of the three HL161AN variants (Table 16), the comparative substance, and the control substance from 24 hours to 120 hours after tracer administration was calculated using the ELISA analysis results.
[0399] The results show that, as shown in Table 22, the half-life of HL161ANS (IgG1-LALA) is 22.7 ± 9.0 hours, the half-life of HL161ANQ (IgG1-LALA) is 15.9 ± 0.9 hours, and the half-life of HL161ANQ (IgG4S228P) is 17.8 ± 2.6 hours. The half-life of the comparative substance HL161AN is 20.6 ± 3.6 hours, which is confirmed to be comparable to the half-life of these three HL161AN variants. In addition, the half-life of the vehicle and IVIG is 108.2 ± 29.0 hours and 98.0 ± 16.8 hours, respectively, confirming that their half-lives are similar. After administering biotin-hIgG, the half-life analysis results of the HL161AN variants in Tg mice are summarized and shown in Table 22 below.
[0400] [Table 22]
[0401]
[0402]
[0403] Example 10. hIgG Catabolism of HL161AN Antibody Variants in hFcRn Transgenic Mice
[0404] The hIgG catabolic effects were confirmed after administration of 20 mg / kg of these three HL161AN variants (engineered to improve the stability of HL161AN) to Tg32 mice. The results showed that HL161ANS (IgG1-LALA), HL161ANQ (IgG1-LALA), and HL161ANQ (IgG4S228P) were confirmed to have hIgG catabolic effects equivalent to those of the comparative substance HL161AN.
[0405] The results showed that HL161ANS (light chain: N32S, heavy chain: C32S) and HL161ANQ (light chain: N32Q, heavy chain: C32S), which are substances in which two amino acids are substituted to improve the stability of the variable domain of HL161AN, were confirmed to have an in vivo IgG decomposition effect similar to that of the original molecule HL161AN. That is, it was confirmed that these three HL161AN variants engineered to improve stability did not affect the in vivo efficacy compared with the existing HL161AN.
[0406] Example 11. hIgG catabolism in hFcRn transgenic mice obtained by administration of anti-FcRn antibody (HL161AN) variants Conclusion
[0407] To evaluate the effects of HL161AN and HL161AN variants (HL161ANS and HL161ANQ) on the catabolism of biotin-hIgG in vivo, blood was collected at different times after administration of 20 mg / kg to Tg32 mice, and the concentration of biotin-hIgG in the blood was determined.
[0408] The results showed that in the case of biotin-hIgG, all three administered substances demonstrated similar biotin-hIgG catabolism. All tested substances (HL161AN, HL161ANS and HL161ANQ) reduced biotin-hIgG concentrations by 90% or more within 120 hours after administration compared to the IVIG control group.
[0409] In conclusion, the hIgG catabolism assay confirmed that the hIgG catabolism effects of HL161ANS and HL161ANQ were not significantly different from those of HL161AN.
[0410] Example 12: Comparison of Antibody HL161ANS and Bartolimumab
[0411] In a head to head study in monkeys, the HL161ANS variant (also known as IMVT-1402) was compared with another anti-FcRn antibody, Batolimumab (HL161BKN, see, e.g., International Patent Application Publication No. WO / 2015 / 167293).
[0412] 50 mg / kg Batolimumab, 5 mg / kg HL161ANS, 50 mg / kg HL161ANS or placebo were given to 20 monkeys in four groups via intravenous route. IgG, albumin, low-density lipoprotein (LDL) and cholesterol were measured at the specified time points. It is known that cynomolgus monkeys are reliable pharmacodynamic representatives of IgG mediated by anti-FcRn (see, e.g., Lledo-Garcia, et al., UCB Pharma, 2022).
[0413] At comparable doses, the effects of Batolimumab and HL161ANS in reducing IgG were almost identical ( Fig.18 ). The IgG lowering effect was dose-dependent. HL161ANS and placebo showed similar effects on albumin, LDL, and cholesterol (respectively FIG. 19A to FIG. 19C ). Therefore, HL161ANS had no substantial effect on albumin, LDL or cholesterol levels.
[0414] Example 13: Exploratory Pharmacology Study with 4 Weeks of Intravenous Dosing Followed by a 4 Week Recovery Period in Cynomolgus Monkeys
[0415] The objectives of this study were to determine the pharmacological, toxicological, and toxicokinetic (TK) characteristics of the test item, HL161ANS, after weekly dosing (on days 1, 8, 15, and 22) in cynomolgus monkeys via intravenous injection for 4 weeks and to assess the persistence, delayed onset, or reversibility of any changes after a 4-week recovery period.
[0416] The test item, positive control item, and control / vehicle item were administered to groups of monkeys once a week by intravenous injection (over a period of approximately 60 seconds) on Days 1, 8, 15, and 22 as described in Table 23 below:
[0417] [Table 23]
[0418]
[0419] a: Control / vehicle animals were administered control / vehicle items (20 mM histidine, 200 mM arginine, pH 6.0, 2% w / v PS-20).
[0420] b: Group 2 animals were given only the positive control item.
[0421] After the last weekly dosing cycle, all animals were observed for 4 weeks, and then animals in Groups 1, 3, and 4 were euthanized and necropsied on day 57.
[0422] The parameters monitored during this study include mortality, clinical observations and body weight. In addition, clinical pathology parameters (hematology, coagulation, clinical chemistry and urinalysis) were assessed. Blood sampling was performed for toxicokinetics, ApoB, IgG and ADA assessments. Autopsy was performed and tissues were collected for possible histopathological examinations.
[0423] No mortality or clinical signs related to HL161ANS were observed.
[0424] No effects on body weight, hematology, coagulation, clinical chemistry, or urinalysis were found to be related to the tested items.
[0425] Of note, spleen plaques were present at 5 mg / kg and 50 mg / kg HL161ANS, and the incidence of small thymus was higher at 50 mg / kg. The toxicological significance of these findings could not be determined because microscopic examinations were not performed.
[0426] In conclusion, HL161ANS was well tolerated in cynomolgus monkeys given once weekly for 4 weeks (days 1, 8, 15, and 22) at doses of 5 mg / kg and 50 mg / kg via intravenous injection.
[0427] Example 14: Six-week subcutaneous and / or intravenous toxicity and toxicokinetic study with HL161 ANS in cynomolgus monkeys plus a 9-week recovery period
[0428] The objectives of this study were to evaluate the toxicity and determine the toxicokinetics of HL161ANS when administered to cynomolgus monkeys via subcutaneous and / or intravenous (slow bolus) injections twice weekly for at least 6 weeks (a total of 13 dosing intervals), and to assess the reversibility or persistence of any effects after a 9-week recovery period.
[0429] Male and female cynomolgus monkeys were divided into six groups and dosed as shown in Table 24. Animals were dosed with a volume of 1.3 mL / kg / dose via subcutaneous (SC) injection (Groups 1 to 4) and / or intravenous (IV)-(slow push) injection (Groups 1, 5 and 6) on days 1, 4, 8, 11, 15, 18, 22, 25, 29, 32, 36, 39 and 43 of the dosing phase. The vehicle control / diluent was HL161 ANS formulation buffer. In addition, each animal was given KLH once on day 14 of the dosing phase and once on day 28 of the recovery phase via subcutaneous injection in a volume of 1 mL / dose.
[0430] [Table 24]
[0431]
[0432] a. Group 1 was given vehicle control only.
[0433] b. The dosing volume for animals was 1.3 mL / kg / dose.
[0434] c. Designate 3 animals / sex / group as late animals and 2 animals / sex / group in Groups 1, 4, and 6 as recovery animals.
[0435] Toxicity was assessed based on mortality, clinical observations, body weight, qualitative food consumption, ophthalmological observations, electrocardiogram (ECG) measurements, skin observations, neurobehavioral observations, respiratory rate assessments, and clinical and anatomical pathology. Blood samples were collected for toxicokinetic, ADA, and immunotoxicology assessments.
[0436] Toxicokinetic parameters were generally similar (within 2-fold) in male and female monkeys. max and AUC 0-72 As indicated by the values, systemic exposure of HL161ANS via SC administration increased with increasing dose levels. 0-72 parameter, this is because the final sacrifice occurred on day 44, so AUC 0-72 The assessment of the effect of 100.0 mg / kg / dose on the serum accumulation of 100.0 mg / kg / dose was limited. The increase was generally greater than proportional at doses between 50.0 mg / kg / dose and 198.4 mg / kg / dose. After repeated subcutaneous dosing twice a week, based on the combined sex-averaged AR, no serum accumulation was observed in the 50.0 mg / kg / dose group from day 1 to day 22, indicating that the values of two individual female animals in this group were substantially below 1.0. Accumulation did occur at higher doses, and the extent of accumulation increased with increasing dose. In the 100.0 mg / kg / dose group (day 1 to day 22), C max and AUC 0-72 The cumulative ratio of C values was 1.65 to 1.86, while in the 198.4 mg / kg / dose group (days 1 to 22 and 43), max and AUC 0-72 The cumulative ratio of the values ranged from 1.83 to 2.88. max and AUC 0-72 The values increased with increasing dose levels. 0-72 Values increased more than proportionally at doses between 50.0 mg / kg / dose and 198.4 mg / kg / dose. max Dose proportionality assessment of the 10 mg / dL dose indicated an approximately dose-proportional increase on day 1, but the dose ratios on days 22 and 43 were difficult to interpret due to this cumulative facilitatory effect. After repeated twice-weekly IV dosing, the C maxSerum accumulation of 10 mg / kg / dose was mild (50.0 mg / kg / dose) to moderate (198.4 mg / kg / dose), with ARs of 1.11 to 1.23 and 1.40 to 1.63, respectively. 0-72 On the other hand, the combined sex mean exposure in the 50.0 mg / kg / dose group decreased by half from day 1 to day 22 and remained constant until day 43, with an AR of approximately 0.460; this indicates that the AR was very low in five of the six animals in this group. AUC of 0.460 was observed in the 198.4 mg / kg / dose IV group. 0-72 Moderate increase, AR is about 1.5. Positive anti-drug antibody (ADA) titers were observed in 35 of 38 animals (92.1%) treated with HL161ANS (1 animal in the 100 mg / kg / dose SC group and 2 animals in the 198.4 mg / kg / dose IV group were ADA-negative). ADA induced by HL161ANS may affect the accumulation rate on days 22 and 43, because AR tends to decrease with increasing ADA titers; the 50 mg / kg / dose group was more affected than the other groups.
[0437] On Day 30 of the dosing period, one female animal dosed SC at 100 mg / kg / dose was euthanized due to emaciated body condition (0.3 kg weight loss), low body condition score, sunken eyes, decreased skin turgor, liquid feces, and low body temperature (36.4°C). The animal had previously been examined and treated for left foot swelling and lacerations on Day 23 of the dosing period; however, the animal's condition worsened. Clinical pathological changes associated with HL161ANS include mild to moderate decreases in total protein and albumin concentrations. These changes were similar to those observed in animals that survived to scheduled euthanasia and may have been exacerbated by clinical observations of inflammatory responses and liquid feces.
[0438] Macroscopic observations included abnormal shape and compression of the brain, which was associated with minimal dilatation of the brainstem observed microscopically, which was considered incidental. The myeloid precursor cell content in the sternal bone marrow was minimally increased, possibly related to the inflammatory response associated with the digital lacerations. Based on microscopic observations, the cause of the moribund state has not been determined, but the continuous liquid stools and digital injuries that resulted in decreased mobility and food consumption may have caused the moribund state of this animal. Based on the available clinical observations and clinical and anatomic pathology results, this mortality was not related to HL161ANS. There were no clinical observations; ophthalmological observations; changes in body weight or food consumption; effects on respiratory rate; skin observations; ECG effects; effects on coagulation, urinalysis, or IgM and IgA titers; effects on CH50 levels; effects on immune and lymphocyte subsets; differences in organ weights; or noteworthy macroscopic findings related to HL161ANS.
[0439] Pre-dose IgM titers on Day 22 of the Dosing Period were notably increased in most controls and male and female animals given ≥50 mg / kg / dose of HL161ANS compared to pre-dose on Day 1 of the Dosing Period. IgM titers in female animals given ≥50 mg / kg / dose of HL161ANS subsequently decreased notably pre-dose and 1344 hours post-dose on Day 43 of the Dosing Period, with values remaining comparable to those of the control group. Pre-dose IgM titers on Day 43 of the Dosing Period in male animals treated with HL161ANS remained comparable to pre-dose IgM titers on Day 22 of the Dosing Period, and notably, IgM titers subsequently decreased 1344 hours post-dose on Day 43 of the Dosing Period. Notably, IgG concentrations decreased pre-dose on Day 4 of the Dosing Period in all animals given ≥50 mg / kg / dose of HL161ANS compared to pre-dose on Day 1 of the Dosing Period. On Day 43 of the Dosing Phase, the mean percent change in IgG concentrations from baseline values for groups given ≥50 mg / kg / dose was approximately 48% to 76%, consistent with expected pharmacology. Mean IgG concentrations for each group increased starting on Day 15 of the Recovery Phase and returned to baseline levels by the end of the Recovery Phase. Compared to pre-dose levels on Day 1 of the Dosing Phase, IgG concentrations in two female animals given SC at 198.4 mg / kg / dose were found to decrease on Day 4 of the Dosing Phase, followed by an increase in IgG concentrations starting on Day 15 of the Dosing Phase. IgG concentrations in both animals remained high until Day 43 of the Dosing Phase, followed by a decrease on the first day of the Recovery Phase. Compared to pre-dose levels on Day 1 of the Dosing Phase, IgG concentrations in one male animal given SC at 198.4 mg / kg / dose were found to decrease on Day 4 of the Dosing Phase, followed by an increase in IgG concentrations starting on Day 15 of the Dosing Phase. IgG concentrations remained high until Day 32 of the Dosing Phase, followed by a decrease on Day 36 of the Dosing Phase. IgG concentrations decreased below baseline until day 50 of the recovery phase. One animal had an increase in IgG concentration that may be related to vascular inflammation seen in various tissues on microscopic examination. The relationship of these changes in mean IgG concentrations in this group to HL161ANS and / or ADA titers is unclear.
[0440] Slight increases in C3a levels were observed on Day 43 of the dosing period in animals dosed SC or IV at 198.4 mg / kg / dose compared to controls and baseline values, and these changes were considered likely to be related to HL161ANS due to consistency and small variations between genders. C3a is an effector in the complement system and has a variety of stimulatory functions on the immune system. Effects related to HL161ANS in clinical chemistry test results included minimal to mild decreases in total protein concentrations on Day 43 of the dosing period in animals dosed SC or IV up to 198.4 mg / kg / dose. Mild to moderate decreases in albumin concentrations were observed on Days 16 and / or 43 of the dosing period in animals dosed SC at >50 mg / kg / dose, male animals dosed IV at >50 mg / kg / dose, and female animals dosed IV at 198.4 mg / kg / dose. Minimal decreases in globulin concentrations were observed in males dosed SC at 50 mg / kg / dose or 100 mg / kg / dose or IV at >50 mg / kg / dose, and in females dosed SC or IV at 50 mg / kg / dose, through Day 43 of the Dosing Period. Males dosed IV at 50 mg / kg / dose showed evidence of reversible albumin effects by Day 43 of the Dosing Period, while all other effects in clinical chemistry test results in animals dosed SC or IV at 198.4 mg / kg / dose showed evidence of reversibility by Day 22 or Day 50 of the Recovery Period.
[0441] Effects associated with HL161ANS in hematologic test results were small in magnitude and included minimal decreases in absolute neutrophil counts on Day 43 of the dosing phase in animals dosed IV at 198.4 mg / kg / dose. These effects showed evidence of reversibility by Day 22 or Day 50 of the recovery phase, except in one male animal dosed IV at 198.4 mg / kg / dose. Notably, one female animal dosed SC at 198.4 mg / kg / dose had a minimal increase in absolute monocyte counts on Day 43 of the dosing phase, which was associated with microscopic findings of vascular inflammation and mononuclear cell infiltration. At terminal sacrifice, there were microscopic findings of vascular inflammation associated with HL161ANS in the lungs, liver, gall bladder, kidneys, stomach, small and large intestine, tongue, heart, uterus, and subcutaneous injection site E in female animals dosed SC at 198.4 mg / kg / dose, which may be associated with injury mediated by immune complexes. Other findings in this animal included minimal extramedullary hematopoiesis and mild hypertrophy of Kupffer cells in the liver, and minimal hypertrophy of the pulmonary tunica media. There were no notable findings related to HL161ANS at the time of sacrifice during the recovery period.
[0442] In summary, male and female cynomolgus monkeys were given vehicle control / diluent or HL161ANS at 50 mg / kg / dose, 100 mg / kg / dose, 198.4 mg / kg / dose twice a week via SC and / or IV injection for six weeks. In animals given 198.4 mg / kg / dose via SC or IV, increased C3A levels were observed on day 43 of the dosing phase. This finding was reversible during the recovery phase. Clinical pathological changes included: slight decreases in total protein concentrations in both males and females dosed up to 198.4 mg / kg / dose via SC or IV; minimal to moderate decreases in albumin concentrations in males and females dosed up to 198.4 mg / kg / dose via SC and IV, males dosed ≥50 mg / kg / dose via IV, and females dosed 198.4 mg / kg / dose via IV; minimal decreases in globulin concentrations in males dosed 50 mg / kg / dose or 100 mg / kg / dose via SC or IV, and females dosed 50 mg / kg / dose via SC or IV; and minimal decreases in absolute neutrophil counts in males and females dosed 198.4 mg / kg / dose via IV. These findings were reversible during the recovery phase.
[0443] Microscopic findings associated with HL161ANS include inflammation of the lungs, liver, gallbladder, kidneys, stomach, small and large intestines, tongue, heart, uterus, and blood vessels in subcutaneous injection site E of a female animal dosed SC at 198.4 mg / kg / dose. There were no findings associated with HL161ANS at the time of sacrifice during the recovery phase. Due to the systemic nature of the microscopic findings of animals dosed SC at 198.4 mg / kg / dose, the effects of this dose were considered to be harmful. Due to the mild severity of the findings and the lack of effect on the health and well-being of animals dosed SC at 100 mg / kg / dose or IV at 198.4 mg / kg / dose, the effects of these doses were considered to be non-harmful. Therefore, the no-observation-of-adverse-effects level (NOAEL) is 100 mg / kg / dose via subcutaneous injection and 198.4 mg / kg / dose via IV injection. The SC dose level corresponds to a mean maximum observed concentration (Cmax) value of 964 mg / L on day 43 of the dosing phase, and an area under the concentration-time curve (AUCtau or AUC0-72) value of 2290 mg / L during the dosing period on day 22 of the dosing phase (it should be noted that the AUC0-72 on day 43 could not be calculated because the final sacrifice was one day after the dose on day 43). The IV dose level corresponds to a mean maximum observed concentration (Cmax) of 7100 mg / L on day 43 of the dosing phase and an area under the concentration-time curve (AUCtau or AUC0-72) value of 2290 mg / L during the dosing period on day 22 of the dosing phase. tau or AUC 0-72) value is 10800mg x day / L.
[0444] Example 15: Subcutaneous and / or intravenous dose-ranging, toxicokinetics and pharmacodynamic studies in cynomolgus monkeys using HL161 ANS to detect toxicity
[0445] The objectives of this study were to evaluate the toxicity and determine the toxicokinetics (TK) and pharmacodynamics (PD) of HL161ANS when administered to cynomolgus monkeys twice weekly via subcutaneous (SC) injections or once weekly via intravenous (IV, slow bolus) injections for at least 6 weeks.
[0446] Male and female cynomolgus monkeys were divided into six groups and dosed as shown in the table below. Animals were dosed with drug at a volume of 1 mL / kg / dose via intravenous injection once a week and / or subcutaneous injection twice a week. The vehicle control / diluent was HL161 ANS formulation buffer.
[0447]
[0448] IV = intravenous; SC = subcutaneous
[0449] a Group 1 was given vehicle control only. On days 1, 8, 15, 22, 29 and 36, the drug was given subcutaneously followed by intravenous administration. On days 4, 11, 18, 25, 32 and 39, the drug was given subcutaneously only.
[0450] b Animals were given the drug in a volume of 1 mL / kg / dose.
[0451] Toxicity assessments were performed based on mortality, clinical observations, body weight, food consumption, skin observations, immunotoxicology, and clinical and anatomic pathology. Blood samples were collected for toxicokinetic assessments and anti-drug antibody analysis.
[0452] There were no HL161ANS-related deaths and no noteworthy clinical or cutaneous observations, changes in body weight, weight gain or food consumption, differences in organ weights, macroscopic observations, or microscopic findings related to HL161ANS.
[0453] Notable clinical chemistry effects associated with HL161ANS in animals given 100 mg / kg / dose via IV or SC were limited to minimal to mild decreases in albumin concentrations noted in individual animals. Albumin reductions were more consistently noted on days 15 or 22 to 50 in animals given 100 mg / kg / dose via SC, while albumin reductions were most notable on days 36 and 43 of the dosing period in animals given 100 mg / kg / dose via IV. The mechanism of albumin reduction is unclear.
[0454] In summary, male and female cynomolgus monkeys were given HL161ANS formulation buffer (vehicle control group) via subcutaneous injection twice a week and intravenous injection once a week, or HL161ANS at 3mg / kg / dose, 10mg / kg / dose or 100mg / kg / dose once a week, or HL161ANS at 100mg / kg / dose via subcutaneous injection twice a week. HL161ANS is well tolerated at all dose levels and in all dose routes. No deaths associated with HL161ANS occurred, and there were no notable clinical observations, weight changes, weight gain, or food consumption, organ weight differences, macroscopic observations, or microscopic findings associated with HL161ANS. No clinical pathological effects associated with HL161ANS were observed in animals given up to 100mg / kg / dose via IV. Notable clinical pathological effects associated with HL161ANS in animals given 100 mg / kg / dose via SC were limited to minimal to mild decreases in albumin concentrations on days 15 or 22 through 50. Based on these findings, 100 mg / kg / dose of HL161ANS via intravenous or subcutaneous injection (the highest dose level given) was considered the maximum tolerated dose (MTD).
[0455] Example 16: Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HL161ANS in Healthy Participants
[0456] This example describes a randomized, placebo-controlled, double-blind, sequential parallel-group Phase 1 study to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of HL161ANS in healthy adult male participants and adult female participants of non-reproductive potential (NCBP). Participants participated in 1 dosing group.
[0457] There are 6 single ascending dose (SAD) arms (100 mg, 300 mg, 600 mg, and 1,200 mg intravenously [IV]; and 300 mg and 600 mg subcutaneously [SC]). There are 2 multiple ascending dose (MAD) arms (300 mg and 600 mg SC once weekly [QW]) and 2 optional MAD arms (150 mg and 450 mg SC QW). Each MAD arm will receive 4 weekly doses of HL161ANS or placebo. Each arm will administer the drug to 2 sentinel individuals (one receiving active substance and one receiving placebo).
[0458] The SAD group each consisted of 6 HL161ANS participants and 2 placebo participants, and the 4 MAD groups each consisted of 10 HL161ANS participants and 2 placebo participants. Thus, the study had a total of 96 participants (HL161ANS 76, placebo 20).
[0459] The selected dose should not exceed a fixed dose of 1,530 mg IV for SAD and 800 mg SC for MAD.
[0460] Participants will be screened to assess eligibility for randomization into the study. In the SAD group, participants will be randomized into 6 consecutive dose groups with 8 participants in each group. In each SAD group, 2 participants will be randomized in a 1:1 ratio to receive HL161ANS or placebo for sentinel dosing, and if HL161ANS is well tolerated in the respective sentinel participant, the remaining 6 participants will be randomized in a 5:1 ratio to receive HL161ANS or placebo.
[0461] In the MAD arm, participants will be randomized into up to 4 sequential arms (2 planned arms and 2 optional arms), each with 12 participants. In each MAD arm, 2 participants will be randomized 1:1 to receive HL161ANS or placebo for sentinel administration, and then, if HL161ANS is well tolerated in the respective sentinel participant, the remaining 10 participants will be randomized 9:1 to receive HL161ANS or placebo.
[0462] The goals and endpoints are shown in Table 25.
[0463] [Table 25]
[0464]
Claims
1. An anti-FcRn antibody or an antigen-binding fragment thereof, comprising: a light chain variable region comprising LCDR1 having the amino acid sequence shown in SEQ ID NO: 1, LCDR2 having the amino acid sequence shown in SEQ ID NO: 2, and LCDR3 having the amino acid sequence shown in SEQ ID NO: 3; and a heavy chain variable region comprising a HCDR1 having an amino acid sequence as shown in SEQ ID NO: 5, a HCDR2 having an amino acid sequence as shown in SEQ ID NO: 6, and a HCDR3 having an amino acid sequence as shown in SEQ ID NO: 7, in, The N3 amino acid in the amino acid sequence shown in SEQ ID NO: 1 is substituted with another amino acid, and / or the C2 amino acid in the amino acid sequence shown in SEQ ID NO: 5 is substituted with another amino acid.
2. The anti-FcRn antibody or antigen-binding fragment thereof according to claim 1, in, The N3 amino acid in the amino acid sequence shown in SEQ ID NO: 1 is substituted with Ser (S) or Gln (Q).
3. The anti-FcRn antibody or antigen-binding fragment thereof according to claim 1 or 2, in, The C2 amino acid in the amino acid sequence shown in SEQ ID NO: 5 is substituted with Ser (S) or Tyr (Y).
4. The anti-FcRn antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, in, The heavy chain variable region comprises a framework consisting of FR1 as shown in SEQ ID NO:15, FR2 as shown in SEQ ID NO:16, FR3 as shown in SEQ ID NO:17 and FR4 as shown in SEQ ID NO:
18.
5. The anti-FcRn antibody or antigen-binding fragment thereof according to claim 4, in, The Q16 amino acid in the amino acid sequence shown in SEQ ID NO: 17 is substituted with another amino acid.
6. The anti-FcRn antibody or antigen-binding fragment thereof according to claim 5, in, The Q16 amino acid in the amino acid sequence shown in SEQ ID NO: 17 is substituted with Glu (E).
7. An anti-FcRn antibody or an antigen-binding fragment thereof, comprising a light chain variable region having the amino acid sequence shown in SEQ ID NO: 4 and a heavy chain variable region having the amino acid sequence shown in SEQ ID NO: 8; in, The N25 amino acid in the amino acid sequence shown in SEQ ID NO:4 is substituted with another amino acid; and the C32 or Q82 amino acid in the amino acid sequence shown in SEQ ID NO:8 is substituted with another amino acid.
8. The anti-FcRn antibody or antigen-binding fragment thereof according to claim 7, in, The amino acid N25 in the amino acid sequence shown in SEQ ID NO: 4 is substituted with Ser (S) or Gln (Q).
9. The anti-FcRn antibody or antigen-binding fragment thereof according to claim 7 or 8, in, The C32 amino acid in the amino acid sequence shown in SEQ ID NO: 8 is substituted with Ser (S) or Tyr (Y).
10. The anti-FcRn antibody or antigen-binding fragment thereof according to any one of claims 7 to 9, in, The amino acid Q82 in the amino acid sequence shown in SEQ ID NO: 8 is substituted with Glu (E).
11. An anti-FcRn antibody or an antigen-binding fragment thereof, comprising: a light chain variable region comprising LCDR1 having the amino acid sequence shown in SEQ ID NO:9, LCDR2 having the amino acid sequence shown in SEQ ID NO:2, and LCDR3 having the amino acid sequence shown in SEQ ID NO:3; and The heavy chain variable region comprises a HCDR1 having an amino acid sequence as shown in SEQ ID NO:11, a HCDR2 having an amino acid sequence as shown in SEQ ID NO:6, and a HCDR3 having an amino acid sequence as shown in SEQ ID NO:
7.
12. The anti-FcRn antibody according to any one of claims 1 to 11, in, The anti-FcRn antibody comprises an Fc region, wherein the Fc region is an IgG1 Fc region or an IgG4 Fc region.
13. The anti-FcRn antibody according to claim 12, in, The Fc region is an IgG1 Fc region comprising Leu234Ala and Leu235Ala amino acid substitutions.
14. A polynucleotide encoding the anti-FcRn antibody or antigen-binding fragment thereof according to any one of claims 1 to 13. A recombinant expression vector comprising the polynucleotide according to claim 14 .
16. A host cell transformed by the recombinant expression vector according to claim 15.
17. A method for producing an anti-FcRn antibody or an antigen-binding fragment thereof, wherein include: Cultivating the host cell of claim 16 to produce antibodies; and The produced antibodies are separated and purified to recover antibodies that specifically bind to FcRn.
18. A pharmaceutical composition comprising the anti-FcRn antibody or antigen-binding fragment thereof according to any one of claims 1 to 13, and a pharmaceutically acceptable carrier.
19. A pharmaceutical composition for treating an autoimmune disease, comprising the anti-FcRn antibody or antigen-binding fragment thereof according to any one of claims 1 to 13.
20. The pharmaceutical composition according to claim 19, in, The autoimmune disease is selected from the group consisting of autoimmune neutropenia, Guillain-Barré syndrome, epilepsy, autoimmune encephalitis, Isaacs syndrome, nevus syndrome, pemphigus vulgaris, pemphigus exfoliativa, bullous pemphigus, epidermolysis bullosa acquisita, pemphigus gestationis, mucous membrane pemphigoid, antiphospholipid syndrome, autoimmune anemia, autoimmune Graves' disease, thyroid eye disease (TED), Goodpasture syndrome, myasthenia gravis, multiple sclerosis, rheumatoid arthritis, lupus, idiopathic thrombocytopenic purpura (ITP), warm autoimmune hemolytic anemia (WAIHA), chronic inflammatory demyelinating polyneuropathy (CIDP), lupus nephritis and membranous nephropathy.
21. A method for treating an autoimmune disease in a subject in need thereof, comprising administering to the subject an anti-FcRn antibody or antigen-binding fragment thereof according to any one of claims 1 to 13, or a pharmaceutical composition according to any one of claims 18 to 20; optionally, wherein the subject is human.
22. The method of claim 21, in, The autoimmune disease is selected from the group consisting of autoimmune neutropenia, Guillain-Barré syndrome, epilepsy, autoimmune encephalitis, Isaacs syndrome, nevus syndrome, pemphigus vulgaris, pemphigus exfoliativa, bullous pemphigus, epidermolysis bullosa acquisita, pemphigus gestationis, mucous membrane pemphigoid, antiphospholipid syndrome, autoimmune anemia, autoimmune Graves' disease, thyroid eye disease (TED), Goodpasture syndrome, myasthenia gravis, multiple sclerosis, rheumatoid arthritis, lupus, idiopathic thrombocytopenic purpura (ITP), warm autoimmune hemolytic anemia (WAIHA), chronic inflammatory demyelinating polyneuropathy (CIDP), lupus nephritis and membranous nephropathy.
23. The method according to claim 21 or 22, in, The administration is parenteral.
24. The method of claim 23, in, The administration is subcutaneous or intravenous.
25. The method according to any one of claims 21 to 24, in, The administration is at a dose of 300 mg to 2400 mg.
26. The method according to any one of claims 21 to 24, in, The administration is once a week, once every two weeks, once every three weeks, or once a month.
27. The method according to any one of claims 21 to 26, in, The administration is a dose of 300 mg to 900 mg subcutaneously once a week.
28. The method according to any one of claims 21 to 26, in, The administration is a biweekly subcutaneous dose of 300 mg to 1800 mg.
29. The method according to any one of claims 21 to 28, in, The administration does not cause the subject's blood albumin level to decrease by more than 5% or more than 10% compared to the blood albumin level before administration of the anti-FcRn antibody or antigen-binding fragment thereof.
30. The method according to any one of claims 21 to 29, in, The administration does not increase the subject's blood total cholesterol or low-density lipoprotein (LDL) level by more than 5% or more than 10% compared to the blood total cholesterol or low-density lipoprotein (LDL) level before administration of the anti-FcRn antibody or antigen-binding fragment thereof.
Citation Information
Patent Citations
FcRn specific human antibody and composition for treatment of autoimmune diseases
KR101815265B1
Antibody Binding to FcRn for Treating Autoimmune Diseases
KR101954906B1
Guanidine derivative
KR1020220066176A
Antibody binding to FCRN for treating autoimmune diseases
WO2015167293A1
Cited By
Anti-FCRN antibodies and methods of use thereof
WO2026136830A1
